Timothy Yap, MBBS, PhD, FRCP

Peer-Reviewed Articles

1. Garmezy B, Gheeya J, Lin HY, Huang Y, Kim T, Jiang X, Thein KZ, Pilie PG, Zeineddine F, Wang W, Shaw KR, Rodon J, Shen JP, Yuan Y, Meric-Bernstam F, Chen K, Yap TA. Clinical and Molecular Characterization of POLE Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers. JCO Precis Oncol 6:e2100267, 2022. PMID: 35108036.
2. Yap TA, Hamilton E, Bauer T, Dumbrava EE, Jeselsohn R, Enke A, Hurley S, Lin KK, Habeck J, Giordano H, Shapiro GI. Phase Ib SEASTAR Study: Combining Rucaparib and Sacituzumab Govitecan in Patients With Cancer With or Without Mutations in Homologous Recombination Repair Genes. JCO Precis Oncol 6:e2100456, 2022. PMID: 35138920.
3. Yap TA, Jacobs I, Baumfield Andre E, Lee LJ, Beaupre D, Azoulay L. Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development. Front Oncol 11:695936, 2022. PMID: 35070951.
4. Coleman N, Subbiah V, Pant S, Patel K, Roy-Chowdhuri S, Yedururi S, Johnson A, Yap TA, Rodon J, Shaw K, Meric-Bernstam F. Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. NPJ Precis Oncol 5(1):99, 2021. PMID: 34853384.
5. Thein KZ, Piha-Paul SA, Tsimberidou A, Karp DD, Janku F, Fu S, Subbiah V, Hong DS, Yap TA, Shah J, Milton DR, McQuinn, Gong J, Tran Y, Carter BW, Colen R, Meric-Bernstam F, Naing A. Selinexor in combination with standard chemotherapy in patients with advanced or metastatic solid tumors. Exp Hematol Oncol 10:59, 2021. PMID: 34965890.
6. Coleman N, Moyers JT, Harbery A, Vivanco I, Yap TA. Clinical Development of AKT Inhibitors and Associated Predictive Biomarkers to Guide Patient Treatment in Cancer Medicine. Pharmgenomics Pers Med 14:1517-1535, 2021. PMID: 34858045.
7. Ngoi NYL, Leo E, O’Connor MJ, Yap TA. Development of Next-Generation Poly(ADP-Ribose) Polymerase 1-Selective Inhibitors. Cancer J 27(6):521-528, 2021. PMID: 34904816.
8. Yap TA, Coleman RL. The Principles and Practice of PARP Inhibitor Therapy. Cancer J 27(6):430-431, 2021. PMID: 34904805.
9. Ngoi NYL, Pham MM, Tan DSP, Yap TA. Targeting the replication stress response through synthetic lethal strategies in cancer medicine. Trends Cancer 7(10):930-957, 2021. e-Pub 2021. PMID: 34215565.
10. Jhaveri K, Burris Rd HA, Yap TA, Hamilton E, Rugo HS, Goldman JW, Dann S, Liu F, Wong GY, Krupka H, Shapiro GI. The evolution of cyclin dependent kinase inhibitors in the treatment of cancer. Expert Rev Anticancer Ther 21(10):1105-1124, 2021. e-Pub 2021. PMID: 34176404.
11. Pham MM, Ngoi NYL, Peng G, Tan DSP, Yap TA. Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises. Trends Cancer 7(10):958-970, 2021. e-Pub 2021. PMID: 34158277.
12. Hobbs EA, Litton JK, Yap TA. Development of the PARP inhibitor talazoparib for the treatment of advanced BRCA1 and BRCA2 mutated breast cancer. Expert Opin Pharmacother 22(14):1825-1837, 2021. e-Pub 2021. PMID: 34309473.
13. Ngoi NYL, Peng G, Yap TA. A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade. Annu Rev Med. e-Pub 2021. PMID: 34644155.
14. Yap TA, Vieito M, Baldini C, Sepúlveda-Sánchez JM, Kondo S, Simonelli M, Cosman R, van der Westhuizen A, Atkinson V, Carpentier AF, Löhr M, Redman R, Mason W, Cervantes A, Le Rhun E, Ochsenreither S, Warren L, Zhao Y, Callies S, Estrem ST, Man M, Gandhi L, Avsar E, Melisi D. First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer. Clin Cancer Res. e-Pub 2021. PMID: 34548321.
15. Dev R, Zhong LL, Zarifa A, Albittar AA, Rubin L, Liu S, Yap TA, Dalal S, Hui D, Karp DD, Tsimberidou AM, Piha-Paul SA, Ahnert JR, Fu S, Meric-Bernstam F, Naing A. Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study. Invest New Drugs. e-Pub 2021. PMID: 34559346.
16. Thein KZ, Karp DD, Tsimberidou A, Gong J, Sulovic S, Shah J, Milton DR, Hong DS, Janku F, McQuinn L, Stephen BA, Colen R, Carter BW, Yap TA, Piha-Paul SA, Fu S, Meric-Bernstam F, Naing A. Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: Results of a single-center, multi-arm phase Ib study. Invest New Drugs. e-Pub 2021. PMID: 34562230.
17. Kato S, Adashek JJ, Subbiah V, Fu S, Sun M, Nguyen L, Brown EJ, Yap TA, Karp DD, Piha-Paul SA, Hong DS. A phase I study of ixazomib and erlotinib in patients with advanced solid tumors. Invest New Drugs, 2021. PMID: 34468905.
18. Shapiro GI, Wesolowski R, Devoe C, Lord S, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R, Yap TA. Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours. Br J Cancer 125(4):520-527, 2021. e-Pub 2021. PMID: 34040174.
19. Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, Wendl MC, Davies SR, Bailey MH, Primeau TM, Hoog J, Mudd JL, Dean DA 2nd, Patidar R, Chen L, Wyczalkowski MA, Jayasinghe RG, Rodrigues FM, Terekhanova NV, Li Y, Lim KH, Wang-Gillam A, Van Tine BA, Ma CX, Aft R, Fuh KC, Schwarz JK, Zevallos JP, Puram SV, Dipersio JF; NCI PDXNet Consortium, Davis-Dusenbery B, Ellis MJ, Lewis MT, Davies MA, Herlyn M, Fang B, Roth JA, Welm AL, Welm BE, Meric-Bernstam F, Chen F, Fields RC, Li S, Govindan R, Doroshow JH, Moscow JA, Evrard YA, Chuang JH, Raphael BJ, Ding L. Yap TA (Collaborator). Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nature Communications 12(1):5086, 2021. PMID: 34429404.
20. Yap TA, Krebs MG, Postel-Vinay, El-Khouiery A, Soria J-C, Lopez J, Berges A, Cheung SYA, Arana II, Goldwin, Felicetti B, Jones GN, Lau A, Frewer P, Pierce AJ, Clack G, Stephens C, Smith SA, Dean E, Hollingsworth SJ. Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a Phase I study. Clin Cancer Res, 2021. PMID: 34301752.
21. Alhalabi O, Hahn AW, Msaouel P, Meric-Bernstam F, Wilson N, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Beltran K, Campbell E, Le H, Campbell MT, Shah A, Tannir NM, Siefker-Radtke A, Gao J, Roszik J, Subbiah V. Validation of Prognostic Scores in Patients With Metastatic Urothelial Cancer Enrolling in Phase I Targeted Therapy or Next Generation Immunotherapy Trials. Clin Genitourin Cancer S1558-7673(21):00132-4, 2021. PMID: 34362693.
22. Giuliani V, Miller MA, Liu CY, Hartono SR, Class CA, Bristow CA, Suzuki E, Sanz LA, Gao G, Gay JP, Feng N, Rose JL, Tomihara H, Daniele JR, Peoples MD, Bardenhagen JP, Geck Do MK, Chang QE, Vangamudi B, Vellano C, Ying H, Deem AK, Do KA, Genovese G, Marszalek JR, Kovacs JJ, Kim M, Fleming JB, Guccione E, Viale A, Maitra A, Emilia Di Francesco M, Yap TA, Jones P, Draetta G, Carugo A, Chedin F, Heffernan TP. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma. Nature Communications 12(1):4626, 2021. PMID: 34330913.
23. Yap TA, Nakagawa K, Fujimoto N, Kuribayashi K, Guren TK, Calabrò L, Shapira-Frommer R, Gao B, Kao S, Matos I, Planchard D, Chatterjee A, Jin F, Norwood K, Kindler HL. Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 study. Lancet Respir Med 9(6):613-621, 2021. e-Pub 2021. PMID: 33836153.
24. Tang Z, Pilie PG, Geng C, Manyam GC, Yang G, Park S, Wang D, Peng S, Wu C, Peng G, Yap TA, Corn PG, Broom BM, Thompson TC. ATR inhibitor-induced CDK1-SPOP axis destabilizes PD-L1 and enhances cytotoxicity in prostate cancer. Clin Cancer Res. e-Pub 2021. PMID: 34168048.
25. Yam C, Ma BBY, Yap TA. Global Implementation of Precision Oncology. JCO Precis Oncol 5, 2021. e-Pub 2021. PMID: 34250385.
26. Yap TA, Parkes EE, Peng W, Moyers JT, Curran MA, Tawbi HA. Development of Immunotherapy Combination Strategies in Cancer. Cancer Discovery 11:1-30, 2021. PMID: 33811048.
27. Coleman N, Zhang B, Byers LA, Yap TA. The role of Schlafen 11 (SLFN11) as a predictive biomarker for targeting the DNA damage response. Br J Cancer 124(5):857-859, 2021. e-Pub 2020. PMID: 33328609.
28. Yap TA, Siu LL, Calvo E, Lolkema MP, LoRusso PM, Soria J, Plummer R, de Bono JS, Tabernero J, Banerji U. SARS-CoV-2 vaccination and phase 1 cancer clinical trials. Lancet Oncol 22(3):298-301, 2021. PMID: 33571468.
29. Collins DC, Sundar R, Constantinidou A, Dolling D, Yap TA, Popat S, O'Brien ME, Banerji U, de Bono JS, Lopez JS, Tunariu N, Minchom A. Correction to: Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. BMC Cancer 21:245, 2021. PMID: 33685408.
30. Jiang L, Li R, Yan F, Yap TA, Yuan Y. Shotgun: A Bayesian seamless phase I-II design to accelerate the development of targeted therapies and immunotherapy. Contemporary Clinical Trials 104, 2021. PMID: 33711459.
31. Hedge A, Jayaprakash P, Couillault CA, Piha-Paul S, Karp D, Rodon J, Pant S, Fu S, Ileana Dumbrava EE, Yap TA, Subbiah V, Bhosale P, Coarfa C, Higgins JP, Williams ET, Wilson TF, Lim J, Meric-Bernstam F, Summer E, Zain H, Nguyen D, Nguyen LM, Rajakshe K, Curran MA, Hong DS. A Phase I Dose Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. Clinical Cancer Research, 2021. PMID: 33771853.
32. Huey R, Georg G, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul SA, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon Ahnert J, Meric-Bernstam F, Shih YT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Journal of Clinical Oncology, 2021. PMID: 33783054.
33. Majd NK, Yap TA, Koul D, Balasubramaniyan V, Li X, Khan S, Gandy KS, Yung WKA, de Groot JF. The promise of DNA damage response inhibitors for the treatment of glioblastoma. Neurooncol Adv 3(1), 2021. PMID: 33738447.
34. Park M, Liu S, Yap TA, Yuan Y. Evaluation of Deviation From Planned Cohort Size and Operating Characteristics of Phase 1 Trials. JAMA Netw Open 4(2), 2021. PMID: 33595664.
35. Yap TA, Johnson A, Meric-Bernstam F. Precision Medicine in Oncology—Toward the Integrated Targeting of Somatic and Germline Genomic Aberrations. JAMA Oncol 4(2), 2021. PMID: 33630035.
36. Pilié PG, George A, Yap TA. Patient Selection Biomarker Strategies for PARP Inhibitor Therapy. Ann Oncol 31(12):1603-1605, 2020. e-Pub 2020. PMID: 33011228.
37. Abdel-Wahab R, Yap TA, Madison R, Pant S, Cooke M, Wang K, Zhao H, Bekaii-Saab T, Karatas E, Kwong LN, Meric-Bernstam F, Borad M, Javle M. Genomic profiling reveals high frequency of DNA repair genetic aberrations in gallbladder cancer. Sci Rep 10(1):22087, 2020. PMID: 33328484.
38. Collins DC, Sundar R, Constantidinou A, Dolling D, Yap TA, Popat S, O’Brien ME, Banerji U, de Bono JS, Lopez JS, Tunariu N, Minchom A. Radiological evaluation of malignant pleural mesothelioma - defining distant metastatic disease. BMC Cancer 20(1):1210, 2020. PMID: 33298007.
39. Alhalabi O, Hahn AW, Msaouel P, Andreev-Drakhlin AY, Meric-Bernstam F, Naing A, Piha-Paul S, Janku F, Pant S, Yap TA, Hong DS, Fu S, Karp D, Campbell E, Le H, Campbell MT, Shah AY, Tannir NM, Siefker-Radtke AO, Gao J, Roszik J, Subbiah V. Molecular profiling of metastatic bladder cancer early-phase clinical trial participants predicts patient outcomes. Mol Cancer Res, 2020. PMID: 33323389.
40. Wang L, Yang L, Wang C, Zhao W, Ju Z, Zhang W, Shen J, Peng Y, An C, Luu YT, Song S, Yap TA, Ajani JA, Mills GB, Shen X, Peng G. Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. J Clin Invest 130(11):5951-5966, 2020. PMID: 33016929.
41. Patnaik A, Yap TA, Chung HC, de Miguel M, Bang Y, Lin C, Su W, Italiano A, Hoong Chow K, Szpurka AM, Yu D, Zhao Y, Carlsen M, Schmidt S, Vangerow B, Gandhi L, Xu X, Bendell JC. Safety and clinical activity of a new anti-PD-L1 antibody as monotherapy or combined with targeted therapy in advanced solid tumors: the PACT phase Ia/Ib trial. Clin Cancer Res, 2020. PMID: 33229456.
42. Hahn AW, Alhalabi O, Msaouel P, Meric-Bernstam F, Naing A, Jonasch E, Piha-Paul S, Hong D, Pant S, Yap T, Campbell E, Le H, Tannir NM, Roszik J, Subbiah V. Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. ESMO Open 5(6):e001073, 2020. PMID: 33229506.
43. Pettitt SJ, Frankum JR, Punta M, Lise S, Alexander J, Chen Y, Yap TA, Haider S, Tutt ANJ, Lord CJ. Clinical BRCA1/2 reversion analysis identifies hotspot mutations and predicted neoantigens associated with therapy resistance. Cancer Discov 10(10):1475-1488, 2020. e-Pub 2020. PMID: 32699032.
44. Yap TA, Kristeleit R, Michalarea V, Pettitt SJ Lim JSJ, Carreira S, Roda D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Rodriguez DN, Ward S, Mattews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner NC, Ruddle R, Raynaud FI, Decordova S, Swales KE, Finneran L, Hall E, Rugman P, Lindemann JPO, Fozley A, Lord CJ, Banerji U, Plummer R, Basu B, Lopez JS, Drew Y, de Bono JS. Phase I Trial of the PARP Inhibitor Olaparib and AKT Inhibitor Capivasertib in Patients with BRCA1/2- and Non- BRCA1/2-Mutant Cancers. Cancer Discov 10(10):1528-1543, 2020. PMID: 3253274.
45. Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, Yap TA, Jankku F, Tsimberisou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer 8(2):e000931, 2020. PMID: 33097611.
46. Yap TA, Tan DSP, Terbuch A, Caldwell R, Guo C, Goh BC, Heong V, Haris N, Bashir S, Drew Y, Hong DS, Meric-Bernstam F, Wilkinson G, Hreiki J, Wengner AM, Bladt F, Schlicker A, Ludwig M, Zhou Y, Liu L, Bordia S, Plummer R, Lagkadinou E, de Bono JS. First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors. Cancer Discovery, 2020. PMID: 32988960.
47. Pascual J, Lim JSJ, Macpherson IRJ, Armstrong AC, Ring A, Okines AF, Cutts RJ, Herrera-Abreu MT, Garcia-Murillas I, Pearson A, Hrebien S, Gevensleben H, Proszek PZ, HUbank M, Hills M, King J, Parmar M, Prout T, Finneran L, Malia J, Swales KE, Ruddle R, Raynaud FI, Turner A, Hall E, Yap TA, Lopez JS, Turner NC. Triplet therapy with palbociclib, taselisib and fulvestrant in PIK3CA mutant breast cancer and doublet palbociclib and taselisib in pathway mutant solid cancers. Cancer Discovery, 2020. PMID: 32958578.
48. Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O’Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, Forster M, Farley A, Wherton D, Mehmi M, Sharpe R, Mills TC, Cerone MA, Yap TA, Watkins TBK, Lim E, Swanton C, Billingham L. Publisher Correction: The National Lung Matrix Trial of personalized therapy in lung cancer. Nature 585(7826):E21, 2020. PMID: 32887973.
49. Middleton G, Fletcher P, Popat S, Savage J, Summers Y, Greystoke A, Gilligan D, Cave J, O'Rourke N, Brewster A, Toy E, Spicer J, Jain P, Dangoor A, Mackean M, Forster M, Farley A, Wherton D, Mehmi M, Sharpe R, Mills TC, Cerone MA, Yap TA, Watkins TBK, Lim E, Swanton C, Billingham L. The National Lung Matrix Trial of personalized therapy in lung cancer. Nature, 2020. PMID: 32669708.
50. Frumovitz M, Westin SN, Salvo G, Zarifa A, Xu M, Yap TA, Rodon AJ, Karp DD, Abonofal A, Jazaeri AA, Naing A. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecology Oncology, 2020. PMID: 32534809.
51. Yap TA, Kristeleit R, Michaelarea V, Pettitt SJ, Lim JSJ, Carreira S, Roda D, Miller R, Riisnaes R, Miranda S, Figueiredo I, Nava Rodrigues D, Ward S, Matthews R, Parmar M, Turner A, Tunariu N, Chopra N, Gevensleben H, Turner NC, Ruddle R, Raynaud FI, Decordova SA, Swales KE, Finneran L, Hall E, Rugman P, Lindemann JPO, Foxley A, Lord CJ, Banerji U, Plummer R, Basu B, Lopez JS, Drew Y, de Bono JS. Phase I trial of the poly(ADP-ribose)Timothy A. Yap, MBBS, PhD, FRCP Page 17 of 46 polymerase (PARP) inhibitor olaparib and AKT inhibitor capivasertib in patients with BRCA1/2 and non-BRCA1/2 mutant cancers. Cancer Discovery, 2020.
52. Yap TA, O'Carrigan B, Penney MS, Lim JS, Brown JS, de Miguel Luken MJ, Tunariu N, Perez-Lopez R, Rodrigues DN, Riisnaes R, Figueiredo I, Carreira S, Hare B, McDermott K, Khalique S, Williamson CT, Natrajan R, Pettitt SJ, Lord CJ, Banerji U, Pollard J, Lopez J, de Bono JS. Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. Journal of Clinical Oncology, 2020. PMID: 32568634.
53. Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. Journal for ImmuoTherapy of Cancer, 2020. PMID: 32188704.
54. Yap TA, Winter JN, Giulino-Roth L, Longley J, Lopez J, Michot JM, Leonard JP, Ribrag V, McCabe MT, Creasy CL, Stern M, Pene Dumitrescu T, Wang X, Frey S, Carver J, Horner T, Oh C, Khaled A, Dhar A, Johnson PWM. Phase 1 study of the novel enhancer of zeste homolog 2 (EZH2) inhibitor GSK2816126 in patients with advanced hematological and solid tumors. Clin Cancer Res 25(24):7331-7339, 2019. e-Pub 2019. PMID: 31471312.
55. Pant S, Maitra A, Yap TA. PARP inhibition - opportunities in pancreatic cancer. Nat Rev Clin Oncol 16(10):595-596, 2019. PMID: 31332344.
56. Pilié PG, Gay CM, Byers LA, O'Connor MJ, Yap TA. PARP Inhibitors: Extending Benefit Beyond BRCA Mutant Cancers. Clin Cancer Res 25(13):3759-3771, 2019. e-Pub 2019. PMID: 30760478.
57. George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, Yap TA, Cleeland CS, Hong DS. Improving attribution of adverse events in oncology clinical trials. Cancer Treat Rev 76:33-40, 2019. e-Pub 2019. PMID: 31108240.
58. Fang Y, McGrail DJ, Sun C, Labrie M, Chen X, Zhang D, Ju Z, Vellano CP, Lu Y, Li Y, Jeong KJ, Ding Z, Liang J, Wang SW, Dai H, Lee S, Sahni N, Mercado-Uribe I, Kim TB, Chen K, Lin SY, Peng G, Westin SN, Liu J, O'Connor MJ, Yap TA, Mills GB. Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy. Cancer Cell 35(6):851-867.e7, 2019. PMID: 31185210.
59. Pilié PG, Tang C, Mills GB, Yap TA. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol 16(2):81-104, 2019. e-Pub 2018. PMID: 30356138.
60. Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL. Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology. J Natl Cancer Inst 111(2):118-128, 2019. e-Pub 2018. PMID: 30561713.
61. Shen J, Zhao W, Ju Z, Wang L, Peng Y, Labrie M, Yap TA, Mills GB, Peng G. PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness. Cancer Res 79(2):311-319, 2019. e-Pub 2018. PMID: 30482774.
62. Yap TA, Plummer R, Azad NS, Helleday T. The DNA Damaging Revolution: PARP Inhibitors and Beyond. Am Soc Clin Oncol Educ Book 39:185-195, 2019. e-Pub 2019. PMID: 31099635.
63. Janku F, Hess KR, Yap TA. Moving Precision Oncology Forward Amid Myths and Misconceptions. JAMA Oncol 4(12):1788-1789, 2018. PMID: 30419079.
64. Stewart RA, Pilié PG, Yap TA. Development of PARP and Immune-Checkpoint Inhibitor Combinations. Cancer Res 78(24):6717-6725, 2018. e-Pub 2018. PMID: 30498083.
65. O'Carrigan B, Lim JSJ, Jalil A, Harris SJ, Papadatos-Pastos D, Banerji U, Lopez J, de Bono JS, Yap TA. Target-based therapeutic matching of phase I trials in patients with metastatic breast cancer in a tertiary referral centre. Br J Cancer 119(8):922-927, 2018. e-Pub 2018. PMID: 30318518.
66. Al-Saffar NMS, Troy H, Wong Te Fong AC, Paravati R, Jackson LE, Gowan S, Boult JKR, Robinson SP, Eccles SA, Yap TA, Leach MO, Chung YL. Metabolic biomarkers of response to the AKT inhibitor MK-2206 in pre-clinical models of human colorectal and prostate carcinoma. Br J Cancer 119(9):1118-1128, 2018. e-Pub 2018. PMID: 30377337.
67. Ileana Dumbrava EE, Mills GB, Yap TA. Targeting gamma secretase: has progress moved up a notch?. Ann Oncol 29(9):1889-1891, 2018. e-Pub 2018. PMID: 30084907.
68. Tang C, Jiang W, Yap TA. Efficacy and Toxic Effects of Cancer Immunotherapy Combinations-A Double-Edged Sword. JAMA Oncol 4(8):1116-1117, 2018. e-Pub 2018. PMID: 29327039.
69. Ileana Dumbrava E, Meric-Bernstam F,Yap TA. Challenges with biomarkers in cancer drug discovery and development. Expert Opin Drug Discov 13(8):1-6, 2018. e-Pub 2018. PMID: 29792354.
70. O'Brien MER, Sarker D, Bhosle J, Thillai K, Yap TA, Uttenreuther-Fischer M, Pemberton K, Jin X, Wiebe S, de Bono J, Spicer J. A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. e-Pub 2018. PMID: 30088048.
71. Kurnit KC, Dumbrava EEI, Litzenburger B, Khotskaya YB, Johnson AM, Yap TA, Rodon J, Zeng J, Shufean MA, Bailey AM, Sánchez NS, Holla V, Mendelsohn J, Shaw KM, Bernstam EV, Mills GB, Meric-Bernstam F. Precision Oncology Decision Support: Current Approaches and Strategies for the Future. Clin Cancer Res 24(12):2719-2731, 2018. e-Pub 2018. PMID: 29420224.
72. Subbiah V, Rodon J, Yap TA. Precision oncology: East meets West. Int J Cancer 142(9):1734-1737, 2018. e-Pub 2018. PMID: 29243227.
73. Janku F, Yap TA, Meric-Bernstam F. Targeting the PI3K pathway in cancer: are we making headway?. Nat Rev Clin Oncol 15(5):273-291, 2018. e-Pub 2018. PMID: 29508857.
74. Raghav K, Bailey AM, Loree JM, Kopetz S, Holla V, Yap TA, Wang F, Chen K, Salgia R, Hong D. Untying the gordion knot of targeting MET in cancer. Cancer Treat Rev 66:95-103, 2018. e-Pub 2018. PMID: 29730462.
75. Lam M, Pant S, Yap TA. Combination drug development in BRAF mutant colorectal cancer. Oncoscience 5(3-4):51-53, 2018. e-Pub 2018. PMID: 29854866.
76. Sun C, Yin J, Fang Y, Chen J, Jeong KJ, Chen X, Vellano CP, Ju Z, Zhao W, Zhang D, Lu Y, Meric-Bernstam F, Yap TA, Hattersley M, O'Connor MJ, Chen H, Fawell S, Lin SY, Peng G, Mills GB. BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency. Cancer Cell 33(3):401-416.e8, 2018. PMID: 29533782.
77. Yap TA, Rodon J. Development of Molecularly Driven Targeted Combination Strategies. Oncologist 22(12):1421-1423, 2017. e-Pub 2017. PMID: 29038233.
78. Pilié PG, LoRusso PM, Yap TA. Precision Medicine: Progress, Pitfalls, and Promises. Mol Cancer Ther 16(12):2641-2644, 2017. PMID: 29203693.
79. Evans KW, Yuca E, Akcakanat A, Scott SM, Arango NP, Zheng X, Chen K, Tapia C, Tarco E, Eterovic AK, Black DM, Litton JK, Yap TA, Tripathy D, Mills GB, Meric-Bernstam F. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors. Clin Cancer Res 23(21):6468-6477, 2017. PMID: 29093017.
80. Vishwanathan K, Dickinson PA, Bui K, Cassier PA, Greystoke A, Lisbon E, Moreno V, So K, Thomas K, Weilert D, Yap TA, Plummer R. The Effect of Food or Omeprazole on the Pharmacokinetics of Osimertinib in Patients With Non-Small-Cell Lung Cancer and in Healthy Volunteers. J Clin Pharmacol. e-Pub 2017. PMID: 29178442.
81. Perez-Lopez R, Roda D, Jimenez B, Brown J, Mateo J, Carreira S, Lopez J, Banerji U, Molife LR, Koh DM, Kaye SB, de Bono JS, Tunariu N, Yap TA. High frequency of radiological differential responses with poly(ADP-Ribose) polymerase (PARP) inhibitor therapy. Oncotarget 8(61):104430-104443, 2017. e-Pub 2017. PMID: 29262651.
82. Capelan M, Roda D, Geuna E, Rihawi K, Bodla S, Kaye SB, Bhosle J, Banerji U, O'Brien M, de Bono JS, Popat S, Yap TA. Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?. Lung Cancer 111:6-11, 2017. e-Pub 2017. PMID: 28838399.
83. Sundar R, Brown J, Ingles Russo A, Yap TA. Targeting ATR in cancer medicine. Curr Probl Cancer 41(4):302-315, 2017. e-Pub 2017. PMID: 28662958.
84. Yap TA, Aerts JG, Popat S, Fennell DA. Novel insights into mesothelioma biology and implications for therapy. Nat Rev Cancer 17(8):475-488, 2017. PMID: 28740119.
85. Sundar R, Hong DS, Kopetz S, Yap TA. Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies. Cancer Discov 7(6):558-560, 2017. PMID: 28576843.
86. Takebe N, Yap TA. Precision Medicine in Oncology. Curr Probl Cancer 41(3):163-165, 2017. e-Pub 2017. PMID: 28372822.
87. Lim JSJ, Janku F, Yap TA. Circulating tumor DNA - from bench to bedside. Curr Probl Cancer 41(3):212-221, 2017. e-Pub 2017. PMID: 28416241.
88. Dolly SO, Collins DC, Sundar R, Popat S, Yap TA. Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs. e-Pub 2017. PMID: 28378229.
89. Saeed R, Gourley C, Rajiv K, Geuna E, Ang JE, Rye T, Chen L, Shapira-Frommer R, Friedlanders M, Matulonis U, De Greve J, Oza AM, Banerjee S, Molife LR, Gore ME, Kaye SB, Yap TA. Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer. Oncotarget. e-Pub 2017.
90. Sundar R, Valeri N, Harrington KJ, Yap TA. Combining Molecularly Targeted Agents: Is More Always Better?. Clin Cancer Res 23(5):1123-1125, 2017. e-Pub 2016. PMID: 27836864.
91. Kumar R, Collins D, Dolly S, McDonald F, O'Brien MER, Yap TA. Targeting the PD-1/PD-L1 axis in non-small cell lung cancer. Curr Probl Cancer 41(2):111-124, 2017. e-Pub 2016. PMID: 28214087.
92. George A, Kristeleit R, Rafii S, Michie CO, Bowen R, Michalarea V, van Hagen T, Wong M, Rallis G, Molife LR, Lopez J, Banerji U, Banerjee SN, Gore ME, de Bono JS, Kaye SB, Yap TA. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. Eur J Cancer 76:52-59. e-Pub 2017. PMID: 28273485.
93. Winfield JM, Tunariu N, Rata M, Miyazaki K, Jerome NP, Germuska M, Blackledge MD, Collins DJ, de Bono JS, Yap TA, deSouza NM, Doran SJ, Koh DM, Leach MO, Messiou C, Orton MR. Extracranial Soft-Tissue Tumors: Repeatability of Apparent Diffusion Coefficient Estimates from Diffusion-weighted MR Imaging. Radiology:161965. e-Pub 2017. PMID: 28301311.
94. Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Petruckevitch A, Jalil A, Capelan M, Michalarea V, Lima J, Diamantis N, Bhosle J, Molife LR, Banerji U, de Bono JS, Popat S, O'Brien ME, Yap TA. Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit. Eur J Cancer 75:56-62. e-Pub 2017. PMID: 28214659.
95. Yap TA, Macklin-Doherty A, Popat S. Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer. Eur J Cancer 70:12-21, 2017. e-Pub 2016. PMID: 27866095.
96. Collins DC, Sundar R, Lim JSJ, Yap TA. Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics. Trends Pharmacol Sci 38(1):25-40, 2017. e-Pub 2016. PMID: 27871777.
97. Lim JS, Sundar R, Chénard-Poirier M, Lopez J, Yap TA. Emerging biomarkers for PD-1 pathway cancer therapy. Biomark Med 11(1):53-67, 2017. e-Pub 2016. PMID: 27936870.
98. Yap TA, Popat S. Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?. J Thorac Oncol 12(1):12-14, 2017. PMID: 27988098.
99. Brown JS, O'Carrigan B, Jackson SP, Yap TA. Targeting DNA Repair in Cancer: Beyond PARP Inhibitors. Cancer Discov 7(1):20-37, 2017. e-Pub 2016. PMID: 28003236.
100. Sundar R, Chénard-Poirier M, Collins DC, Yap TA. Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer. Front Med (Lausanne) 4:39, 2017. e-Pub 2017. PMID: 28443282.
101. Minchom A, Thavasu P, Ahmad Z, Stewart A, Georgiou A, O'Brien MER, Popat S, Bhosle J, Yap TA, de Bono J, Banerji U. A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. PLoS One 12(10):e0186106, 2017. e-Pub 2017. PMID: 28982179.
102. Dolly SO, Kalaitzaki E, Puglisi M, Stimpson S, Hanwell J, Fandos SS, Stapleton S, Ansari T, Peckitt C, Kaye S, Lopez J, Yap TA, van der Graaf W, de Bono J, Banerji U. A study of motivations and expectations of patients seen in phase 1 oncology clinics. Cancer 122(22):3501-3508, 2016. e-Pub 2016. PMID: 27716902.
103. Yap TA, Smith AD, Ferraldeschi R, Al-Lazikani B, Workman P, de Bono JS. Drug discovery in advanced prostate cancer: translating biology into therapy. Nat Rev Drug Discov 15(10):699-718, 2016. e-Pub 2016. PMID: 27444228.
104. Lim JS, Collins D, Yap TA. Emerging strategies for the treatment of advanced small cell lung cancer. J Thorac Dis 8(10):E1249-E1253, 2016. PMID: 27867600.
105. Lim JS, Turner NC, Yap TA. CDK4/6 Inhibitors: Promising Opportunities beyond Breast Cancer. Cancer Discov 6(7):697-9, 2016. PMID: 27371575.
106. Yap TA, Banerji U, de Bono JS, Workman P. Biopsy-Derived Biomarkers in Phase I Trials: Building Confidence in Drug Development. J Clin Oncol 34(20):2431-2, 2016. e-Pub 2016. PMID: 27138581.
107. Sharp A, Bhosle J, Abdelraouf F, Popat S, O'Brien M, Yap TA. Development of molecularly targeted agents and immunotherapies in small cell lung cancer. Eur J Cancer 60:26-39, 2016. e-Pub 2016. PMID: 27060747.
108. Harris SJ, Brown J, Lopez J, Yap TA. Immuno-oncology combinations: raising the tail of the survival curve. Cancer Biol Med 13(2):171-93, 2016. PMID: 27458526.
109. Weller A, O'Brien MER, Ahmed M, Popat S, Bhosle J, McDonald F, Yap TA, Du Y, Vlahos I, deSouza NM. Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer. Eur J Cancer 59:65-78, 2016. e-Pub 2016. PMID: 27016624.
110. Brown JS, Kaye SB, Yap TA. PARP inhibitors: the race is on. Br J Cancer 114(7):713-5, 2016. PMID: 27022824.
111. Yap TA, Gillespie L, Ellison S, Flechas SV, Koo MS, Martinez AE, Vredenburg VT. Invasion of the Fungal Pathogen Batrachochytrium dendrobatidis on California Islands. Ecohealth 13(1):145-50, 2016. e-Pub 2015. PMID: 26493624.
112. Kumar R, Lu SK, Minchom A, Sharp A, Davidson M, Gunapala R, Yap TA, Bhosle J, Popat S, O'Brien ME. A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients. Cancer Chemother Pharmacol 77(2):375-83, 2016. e-Pub 2015. PMID: 26706729.
113. Khan KH, Yap TA, Ring A, Molife LR, Bodla S, Thomas K, Zivi A, Smith A, Judson I, Banerji U, de Bono JS, Kaye SB. Phase I trial outcomes in older patients with advanced solid tumours. Br J Cancer 114(3):262-8, 2016. e-Pub 2016. PMID: 26757260.
114. Puglisi M, Stewart A, Thavasu P, Frow M, Carreira S, Minchom A, Punwani R, Bhosle J, Popat S, Ratoff J, de Bono J, Yap TA, O''Brien M, Banerji U. Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions. Oncology 90(5):280-8, 2016. e-Pub 2016. PMID: 27082424.
115. Geuna E, Roda D, Rafii S, Jimenez B, Capelan M, Rihawi K, Montemurro F, Yap TA, Kaye SB, De Bono JS, Molife LR, Banerji U. Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. Br J Cancer 113(11):1541-7, 2015. e-Pub 2015. PMID: 26554652.
116. Abdelraouf F, Sharp A, Maurya M, Mair D, Wotherspoon A, Leary A, Gonzalez de Castro D, Bhosle J, Nassef A, Gaafar T, Popat S, Yap TA, O'Brien M. Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice. BMC Res Notes 8:688, 2015. e-Pub 2015. PMID: 26581482.
117. Frenel JS, Carreira S, Goodall J, Roda D, Perez-Lopez R, Tunariu N, Riisnaes R, Miranda S, Figueiredo I, Nava-Rodrigues D, Smith A, Leux C, Garcia-Murillas I, Ferraldeschi R, Lorente D, Mateo J, Ong M, Yap TA, Banerji U, Gasi Tandefelt D, Turner N, Attard G, de Bono JS. Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. Clin Cancer Res 21(20):4586-96, 2015. e-Pub 2015. PMID: 26085511.
118. Yap TA, Bjerke L, Clarke PA, Workman P. Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr Opin Pharmacol 23:98-107, 2015. e-Pub 2015. PMID: 26117819.
119. Yap TA, Koo MS, Ambrose RF, Wake DB, Vredenburg VT. BIODIVERSITY. Averting a North American biodiversity crisis. Science 349(6247):481-2, 2015. PMID: 26228132.
120. Rafii S, Roda D, Geuna E, Jimenez B, Rihawi K, Capelan M, Yap TA, Molife LR, Kaye SB, de Bono JS, Banerji U. Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials. Clin Cancer Res 21(8):1869-76, 2015. e-Pub 2015. PMID: 25649020.
121. Tolcher AW, Khan K, Ong M, Banerji U, Papadimitrakopoulou V, Gandara DR, Patnaik A, Baird RD, Olmos D, Garrett CR, Skolnik JM, Rubin EH, Smith PD, Huang P, Learoyd M, Shannon KA, Morosky A, Tetteh E, Jou YM, Papadopoulos KP, Moreno V, Kaiser B, Yap TA, Yan L, de Bono JS. Antitumor activity in RAS-driven tumors by blocking AKT and MEK. Clin Cancer Res 21(4):739-48, 2015. e-Pub 2014. PMID: 25516890.
122. Papadatos-Pastos D, De Miguel Luken MJ, Yap TA. Combining targeted therapeutics in the era of precision medicine. Br J Cancer 112(1):1-3, 2015. PMID: 25562565.
123. Lopez J, Harris S, Roda D, Yap TA. Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials. Transl Oncogenomics 7(Suppl 1):1-11, 2015. e-Pub 2015. PMID: 26609214.
124. Yap TA. Challenges in combining novel molecularly targeted agents in cancer medicine. Ann Oncol 26(1):9-11, 2015. e-Pub 2014. PMID: 25336115.
125. Yap TA, Yan L, Patnaik A, Tunariu N, Biondo A, Fearen I, Papadopoulos KP, Olmos D, Baird R, Delgado L, Tetteh E, Beckman RA, Lupinacci L, Riisnaes R, Decordova S, Heaton SP, Swales K, deSouza NM, Leach MO, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW. Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers. Clin Cancer Res 20(22):5672-85, 2014. e-Pub 2014. PMID: 25239610.
126. Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol 7:70, 2014. e-Pub 2014. PMID: 25277503.
127. Ong M, Carreira S, Goodall J, Mateo J, Figueiredo I, Rodrigues DN, Perkins G, Seed G, Yap TA,. Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. Br J Cancer 111(5):828-36, 2014. e-Pub 2014. PMID: 24983367.
128. Yap TA, Lorente D, Omlin A, Olmos D, de Bono JS. Circulating tumor cells: a multifunctional biomarker. Clin Cancer Res 20(10):2553-68, 2014. PMID: 24831278.
129. Yap TA, Popat S. Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer. Pharmgenomics Pers Med 7:285-95, 2014. e-Pub 2014. PMID: 25278773.
130. Yap TA, Popat S. The role of afatinib in the management of non-small cell lung carcinoma. Expert Opin Drug Metab Toxicol 9(11):1529-39, 2013. e-Pub 2013. PMID: 23985030.
131. Ang JE, Gourley C, Powell CB, High H, Shapira-Frommer R, Castonguay V, De Greve J, Atkinson T, Yap TA, Sandhu S, Banerjee S, Chen LM, Friedlander ML, Kaufman B, Oza AM, Matulonis U, Barber LJ, Kozarewa I, Fenwick K, Assiotis I, Campbell J, Chen L, de Bono JS, Gore ME, Lord CJ, Ashworth A, Kaye SB. Efficacy of chemotherapy in BRCA1/2 mutation carrier ovarian cancer in the setting of PARP inhibitor resistance: a multi-institutional study. Clin Cancer Res 19(19):5485-93, 2013. e-Pub 2013. PMID: 23922302.
132. Khan KH, Yap TA, Yan L, Cunningham D. Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer 32(5):253-65, 2013. PMID: 23642907.
133. Sandhu SK, Omlin A, Hylands L, Miranda S, Barber LJ, Riisnaes R, Reid AH, Attard G, Chen L, Kozarewa I, Gevensleben H, Campbell J, Fenwick K, Assiotis I, Olmos D, Yap TA, Fong P, Tunariu N, Koh D, Molife LR, Kaye S, Lord CJ, Ashworth A, de Bono J. Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. Ann Oncol 24(5):1416-8, 2013. e-Pub 2013. PMID: 23524863.
134. Tan DS, Yap TA, Hutka M, Roxburgh P, Ang J, Banerjee S, Grzybowska E, Gourley C, Gore ME, Kaye SB. Implications of BRCA1 and BRCA2 mutations for the efficacy of paclitaxel monotherapy in advanced ovarian cancer. Eur J Cancer 49(6):1246-53, 2013. e-Pub 2012. PMID: 23265709.
135. Yap TA, Omlin A, de Bono JS. Development of therapeutic combinations targeting major cancer signaling pathways. J Clin Oncol 31(12):1592-605, 2013. e-Pub 2013. PMID: 23509311.
136. Yap TA, Arkenau HT, Camidge DR, George S, Serkova NJ, Gwyther SJ, Spratlin JL, Lal R, Spicer J, Desouza NM, Leach MO, Chick J, Poondru S, Boinpally R, Gedrich R, Brock K, Stephens A, Eckhardt SG, Kaye SB, Demetri G, Scurr M. First-in-human phase I trial of two schedules of OSI-930, a novel multikinase inhibitor, incorporating translational proof-of-mechanism studies. Clin Cancer Res 19(4):909-19, 2013. e-Pub 2013. PMID: 23403628.
137. Yap TA, Pezaro CJ, de Bono JS. Cabazitaxel in metastatic castration-resistant prostate cancer. Expert Rev Anticancer Ther 12(9):1129-36, 2012. PMID: 23098113.
138. Yap TA, Walton MI, Grimshaw KM, Te Poele RH, Eve PD, Valenti MR, de Haven Brandon AK, Martins V, Zetterlund A, Heaton SP, Heinzmann K, Jones PS, Feltell RE, Reule M, Woodhead SJ, Davies TG, Lyons JF, Raynaud FI, Eccles SA, Workman P, Thompson NT, Garrett MD. AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. Clin Cancer Res 18(14):3912-23, 2012. e-Pub 2012. PMID: 22781553.
139. Basu B, Yap TA, Molife LR, de Bono JS. Targeting the DNA damage response in oncology: past, present and future perspectives. Curr Opin Oncol 24(3):316-24, 2012. PMID: 22476188.
140. Arkenau HT, Plummer R, Molife LR, Olmos D, Yap TA, Squires M, Lewis S, Lock V, Yule M, Lyons J, Calvert H, Judson I. A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies. Ann Oncol 23(5):1307-13, 2012. e-Pub 2011. PMID: 22015452.
141. Yap TA, Cortes-Funes H, Shaw H, Rodriguez R, Olmos D, Lal R, Fong PC, Tan DS, Harris D, Capdevila J, Coronado C, Alfaro V, Soto-Matos A, Fernández-Teruel C, Siguero M, Tabernero JM, Paz-Ares L, de Bono JS, López-Martin JA. First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours. Br J Cancer 106(8):1379-85, 2012. PMID: 22491421.
142. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 4(127):127ps10, 2012. PMID: 22461637.
143. Yap TA, Workman P. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol 52:549-73, 2012. PMID: 22235862.
144. Perkins G, Yap TA, Pope L, Cassidy AM, Dukes JP, Riisnaes R, Massard C, Cassier PA, Miranda S, Clark J, Denholm KA, Thway K, Gonzalez De Castro D, Attard G, Molife LR, Kaye SB, Banerji U, de Bono JS. Multi-purpose utility of circulating plasma DNA testing in patients with advanced cancers. PLoS One 7(11):e47020, 2012. e-Pub 2012. PMID: 23144797.
145. Yap TA, Swanton C, de Bono JS. Personalization of prostate cancer prevention and therapy: are clinically qualified biomarkers in the horizon?. EPMA J 3(1):3, 2012. e-Pub 2012. PMID: 22738151.
146. Vitfell-Pedersen J, Yap TA, Moreno V, Baird RD, Khan AZ, Barton DP, Kaye SB. The role of surgery in patients with advanced gynaecological cancers participating in phase I clinical trials. Eur J Gynaecol Oncol 33(2):211-3, 2012. PMID: 22611966.
147. Sandhu SK, Yap TA, de Bono JS. The emerging role of poly(ADP-Ribose) polymerase inhibitors in cancer treatment. Curr Drug Targets 12(14):2034-44, 2011. PMID: 21777194.
148. Yap TA, Sandhu SK, Alam SM, de Bono JS. HGF/c-MET targeted therapeutics: novel strategies for cancer medicine. Curr Drug Targets 12(14):2045-58, 2011. PMID: 21777195.
149. Yap TA, Yan L, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Baird RD, Delgado L, Taylor A, Lupinacci L, Riisnaes R, Pope LL, Heaton SP, Thomas G, Garrett MD, Sullivan DM, de Bono JS, Tolcher AW. First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid tumors. J Clin Oncol 29(35):4688-95, 2011. e-Pub 2011. PMID: 22025163.
150. de Bono JS, Yap TA. c-MET: an exciting new target for anticancer therapy. Ther Adv Med Oncol 3(1 Suppl):S3-5, 2011. PMID: 22128286.
151. de Bono JS, Yap TA. Future directions in the evaluation of c-MET-driven malignancies. Ther Adv Med Oncol 3(1 Suppl):S51-60, 2011. PMID: 22128288.
152. Yap TA, Olmos D, Molife LR, de Bono JS. Targeting the insulin-like growth factor signaling pathway: figitumumab and other novel anticancer strategies. Expert Opin Investig Drugs 20(9):1293-304, 2011. e-Pub 2011. PMID: 21777167.
153. Olmos D, Baird RD, Yap TA, Massard C, Pope L, Sandhu SK, Attard G, Dukes J, Papadatos-Pastos D, Grainger P, Kaye SB, de Bono JS. Baseline circulating tumor cell counts significantly enhance a prognostic score for patients participating in phase I oncology trials. Clin Cancer Res 17(15):5188-96, 2011. e-Pub 2011. PMID: 21531820.
154. Yap TA, Zivi A, Omlin A, de Bono JS. The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 8(10):597-610, 2011. e-Pub 2011. PMID: 21826082.
155. Brunetto A, Olmos D, Arkenau HT, Tan D, Yap TA, de Bono J, Barriuso J, Kaye S. Perceptions and referral trends into phase I oncology trials: results of a clinical survey. Journal of Oncology 2011, 2011.
156. Olmos D, Barker D, Sharma R, Brunetto AT, Yap TA, Taegtmeyer AB, Barriuso J, Medani H, Degenhardt YY, Allred AJ, Smith DA, Murray SC, Lampkin TA, Dar MM, Wilson R, de Bono JS, Blagden SP. Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies. Clin Cancer Res 17(10):3420-30, 2011. e-Pub 2011. PMID: 21459796.
157. Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, Pope L, Clark J, Futreal A, Germuska M, Collins D, deSouza NM, Leach MO, Savage RE, Waghorne C, Chai F, Garmey E, Schwartz B, Kaye SB, de Bono JS. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol 29(10):1271-9, 2011. e-Pub 2011. PMID: 21383285.
158. Yap TA, Walton MI, Hunter LJ, Valenti M, de Haven Brandon A, Eve PD, Ruddle R, Heaton SP, Henley A, Pickard L, Vijayaraghavan G, Caldwell JJ, Thompson NT, Aherne W, Raynaud FI, Eccles SA, Workman P, Collins I, Garrett MD. Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930. Mol Cancer Ther 10(2):360-71, 2011. e-Pub 2010. PMID: 21191045.
159. Yap TA, Sandhu SK, Carden CP, de Bono JS. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J Clin 61(1):31-49, 2011. e-Pub 2011. PMID: 21205831.
160. Brunetto AT, Ang JE, Olmos D, Tan D, Barriuso J, Arkenau HT, Yap TA, Molife LR, Banerji U, de Bono J, Judson I, Kaye S. A study of the pattern of hospital admissions in a specialist Phase I oncology trials unit: unplanned admissions as an early indicator of patient attrition. Eur J Cancer 46(15):2739-45, 2010. e-Pub 2010. PMID: 20667711.
161. Yap TA, de Bono JS, Kaye SB, Tutt A, Ashworth A, Schellens JHM. BRCA1 CpG Island Hypermethylation Predicts Sensitivity to PARP Inhibitors. Journal of Clinical Oncology 28(29):e565-6, 2010.
162. Carden CP, Yap TA, Kaye SB. PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers. Curr Opin Oncol 22(5):473-80, 2010. PMID: 20485165.
163. Yap TA, Vidal L, Adam J, Stephens P, Spicer J, Shaw H, Ang J, Temple G, Bell S, Shahidi M, Uttenreuther-Fischer M, Stopfer P, Futreal A, Calvert H, de Bono JS, Plummer R. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28(25):3965-72, 2010. e-Pub 2010. PMID: 20679611.
164. Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer 10(7):514-23, 2010. e-Pub 2010. PMID: 20535131.
165. Molife LR, Fong PC, Paccagnella L, Reid AH, Shaw HM, Vidal L, Arkenau HT, Karavasilis V, Yap TA, Olmos D, Spicer J, Postel-Vinay S, Yin D, Lipton A, Demers L, Leitzel K, Gualberto A, de Bono JS. The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Br J Cancer 103(3):332-9, 2010. e-Pub 2010. PMID: 20628389.
166. Grimshaw KM, Hunter LJ, Yap TA, Heaton SP, Walton MI, Woodhead SJ, Fazal L, Reule M, Davies TG, Seavers LC, Lock V, Lyons JF, Thompson NT, Workman P, Garrett MD. AT7867 is a potent and oral inhibitor of AKT and p70 S6 kinase that induces pharmacodynamic changes and inhibits human tumor xenograft growth. Mol Cancer Ther 9(5):1100-10, 2010. e-Pub 2010. PMID: 20423992.
167. Yap TA, de Bono JS. Targeting the HGF/c-Met axis: state of play. Mol Cancer Ther 9(5):1077-9, 2010. e-Pub 2010. PMID: 20442310.
168. Fong PC, Yap TA, Boss DS, Carden CP, Mergui-Roelvink M, Gourley C, De Greve J, Lubinski J, Shanley S, Messiou C, A'Hern R, Tutt A, Ashworth A, Stone J, Carmichael J, Schellens JH, de Bono JS, Kaye SB. Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol 28(15):2512-9, 2010. e-Pub 2010. PMID: 20406929.
169. Gourley C, Michie CO, Roxburgh P, Yap TA, Harden S, Paul J, Ragupathy K, Todd R, Petty R, Reed N, Hayward RL, Mitchell P, Rye T, Schellens JH, Lubinski J, Carmichael J, Kaye SB, Mackean M, Ferguson M. Increased incidence of visceral metastases in scottish patients with BRCA1/2-defective ovarian cancer: an extension of the ovarian BRCAness phenotype. J Clin Oncol 28(15):2505-11, 2010. e-Pub 2010. PMID: 20406939.
170. Carden CP, Sarker D, Postel-Vinay S, Yap TA, Attard G, Banerji U, Garrett MD, Thomas GV, Workman P, Kaye SB, de Bono JS. Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?. Drug Discov Today 15(3-4):88-97, 2010. e-Pub 2009. PMID: 19961955.
171. Sandhu SK, Yap TA, de Bono JS. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 46(1):9-20, 2010. PMID: 19926276.
172. Yap TA, Kaye SB, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in BRCA mutation carriers. The New England Journal of Medicine 361(17):1707-1708, 2009.
173. Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 15(15):4799-805, 2009. e-Pub 2009. PMID: 19638457.
174. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 361(2):123-34, 2009. e-Pub 2009. PMID: 19553641.
175. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 9(3):167-81, 2009. PMID: 19238149.
176. Rasheed S, Yap TA, Zia A, McDonald PJ, Glynne-Jones R. Chemoradiotherapy – an alternative to surgery for squamous cell carcinoma of the rectum. Report of six cases and literature review. Colorectal Disease 11(2):191-7, 2009.
177. Yap TA, Brunetto A, Pandha H, Harrington K, Debono JS. Reovirus therapy in cancer: has the orphan virus found a home?. Expert Opin Investig Drugs 17(12):1925-35, 2008. PMID: 19012507.
178. Vidal L, Pandha HS, Yap TA, White CL, Twigger K, Vile RG, Melcher A, Coffey M, Harrington KJ, DeBono JS. A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res 14(21):7127-37, 2008. PMID: 18981012.
179. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26(28):4563-71, 2008. e-Pub 2008. PMID: 18645193.
180. Yap TA, Carden CP, Attard G, de Bono JS. Targeting CYP17: established and novel approaches in prostate cancer. Curr Opin Pharmacol 8(4):449-57, 2008. e-Pub 2008. PMID: 18619560.
181. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS, Workman P. Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8(4):393-412, 2008. e-Pub 2008. PMID: 18721898.
182. Haluska P, Shaw HM, Batzel GN, Yin D, Molina JR, Molife LR, Yap TA, Roberts ML, Sharma A, Gualberto A, Adjei AA, de Bono JS. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 13(19):5834-40, 2007. PMID: 17908976.
183. Yap TA, Molife LR, Blagden SP, de Bono S. Targeting cell cycle kinases and kinesins in anticancer drug development. Expert Opin Drug Discov 2(4):539-60, 2007. PMID: 23484760.
184. Yap TA, Eisen TG. Adjuvant therapy of renal cell carcinoma. Clin Genitourin Cancer 5(2):120-30, 2006. PMID: 17026800.
185. Vidal L, Yap TA, White CL, Twigger K, Hingorani M, Kaye SB, Harrington KJ, de Bono JS. Reovirus and Oncolytic Viruses for the Targeted Treatment of Cancer. Targeted Oncology 1(3):130-150, 2006.
186. Hawkey CR, Yap TA, Pereira J, Moore DA, Davidson RN, Pasvol G, Kon OM, Wall RA, Wilkinson RJ. Characterization and management of paradoxical upgrading reactions in HIV-uninfected patients with lymph node tuberculosis. Clinical Infectious Diseases 40(9):1368-71, 2005.

Invited Articles

1. Yap TA, Zivi A, de Bono JS. Cabazitaxel: A novel drug strategy in castration resistant prostate cancer. Medicine Matters:1-7, 2011.
2. Yap TA. New York nightmare: disaster docs, the story of the emergency services. Trauma 1(1):6-7, 2001.

Manuals, Teaching Aids, Other Teaching Publications

1. Yap TA and Josephs D. The use of biomarkers for treatment decisions in oncology. ESMO E-Learning Module, http://oncologypro.esmo.org/Science-Education/ESMO-E-Learning-and-V-Learning/The-Use-of-Biomarkers-for-Treatment-Decisions-in-Oncology, 2015.
2. Yap TA and Biondo A. Tumour biology – new treatments and predictive biomarkers. The Institute of Cancer Research E-learning module, 2014.

Other Articles

1. Yap TA, LoRusso PM, Wong DJ, Hu-Lieskovan S, Papadopoulos KP, Holz JB, Grabowska U, Gradinaru C, Leung KM, Marshall S, Reader CS, Russell R, Sainson RCA, Seal CJ, Shepherd CJ, Germaschewski F, Gliddon D, Stern O, Young L, Brewis N, Kayitalire L, Morrow M A Phase 1 first-in-human study of FS118, a tetravalent bispecific antibody targeting LAG-3 and PD-L1 in patients with advanced cancer and PD-L1 resistance. Clin Cancer Res 29(5):888-898, 2023. PMID: 36342102.
2. Schram AM, Colombo N, Arrowsmith E, Narayan V, Yonemori K, Scambia G, Zelnak A, Bauer TM, Jin N, Ulahannan SV, Colleoni M, Aftimos P, Donoghue MTA, Rosen E, Rudneva VA, Telli ML, Domchek SM, Galsky MD, Hoyle M, Chappey C, Stewart R, Blake-Haskins JA, Yap TA Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial. JAMA Oncol 9(1):29-39, 2023. PMID: 36394867.
3. Yap TA, Bardia A, Dvorkin M, Galsky MD, Beck JT, Wise DR, Karyakin O, Rubovszky G, Kislov N, Rohrberg K, Joy AA, Telli ML, Schram AM, Conte U, Chappey C, Stewart R, Stypinski D, Michelon E, Cesari R, Konstantinopoulos PA Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial. JAMA Oncol 9(1):40-50, 2023. PMID: 36394849.
4. Vo HH, Fu S, Hong DS, Karp DD, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Rodon J, Ajani JA, Cartwright C, Johnson A, Song IW, Beck J, Kahle M, Nogueras-Gonzalez GM, Miller V, Chao C, Vining DJ, Berry DA, Meric-Bernstam F, Tsimberidou AM Challenges and opportunities associated with the MD Anderson IMPACT2 randomized study in precision oncology. NPJ Precis Oncol, 2022.
5. Bright SJ, Flint DB, Martinus DKJ, Turner BX, Manandhar M, Kacem MB, McFadden CH, Yap TA, Shaitelman SF, Sawakuchi GO Targeted Inhibition of DNA-PKcs, ATM, ATR, PARP, and Rad51 Modulate Response to X Rays and Protons, 2022.
6. Moyers JT, Carmagnani Pestana R, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap T, Karp D, Rodon J, Livingston JA, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102), 2022.
7. Araujo D, Greystoke A, Bates S, Bayle A, Calvo E, Castelo-Branco L, de Bono J, Drilon A, Garralda E, Ivy P, Kholmanskikh O, Melero I, Pentheroudakis G, Petrie J, Plummer R, Ponce S, Postel-Vinay S, Siu L, Spreafico A, Stathis A, Steeghs N, Yap C, Yap TA, Ratain M, Seymour L Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. Ann Oncol, 2022.
8. Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial, 2022.
9. Nelson BE, Ejezie CL, Stephen BA, Nardo M, Campbell E, Gong J, Hong DS, Fu S, Yap TA, Murphy MB, Piha-Paul S, Daver NG, Rojas-Hernandez CM, Naing A Spectrum of Immune Checkpoint Inhibitor Anemias: Results From a Single Center, Early-Phase Clinical Trials Case Series Experience, 2022.

Abstracts

1. Ngoi NYL, Westin SN, Yap TA. Targeting the DNA damage response beyond poly(ADP-ribose) polymerase inhibitors: novel agents and rational combinations. Curr Opin Oncol, 2022.
2. Li X, Dowling EK, Yan G, Dereli Z, Bozorgui B, Imanirad P, Elnaggar JH, Luna A, Menter DG, Pilié PG, Yap TA, Kopetz S, Sander C, Korkut A. Precision Combination Therapies Based on Recurrent Oncogenic Coalterations, 2022.
3. Yap TA, Gainor JF, Callahan MK, Falchook GS, Pachynski RK, LoRusso P, Kummar S, Gibney GT, Burris HA, Tykodi SS, Rahma OE, Seiwert TY, Papadopoulos KP, Blum Murphy M, Park H, Hanson A, Hashambhoy-Ramsay Y, McGrath L, Hooper E, Xiao X, Cohen H, Fan M, Felitsky D, Hart C, McComb R, Brown K, Sepahi A, Jimenez J, Zhang W, Baeck J, Laken H, Murray R, Trehu E, Harvey CJ. First in Human Phase 1/2 ICONIC Trial of the ICOS agonist vopratelimab alone and with nivolumab: ICOS high CD4 T cell populations and predictors of response, 2022.
4. Yap TA, Ashok A, Stoll J, Mauer E, Nepomuceno VM, Blackwell KL, Garber JE, Meric-Bernstam F. Prevalence of Germline Findings Among Tumors From Cancer Types Lacking Hereditary Testing Guidelines. JAMA, 2022.
5. Yao S, Meric-Bernstam F, Hong D, Janku F, Naing A, Piha-Paul SA, Tsimberidou AM, Karp D, Subbiah V, Yap TA, Ahnert JR, Pant S, Dumbrava EEI, Wathoo C, Campbell E, Yu L, Yamamura Y, Fu S. Clinical characteristics and outcomes of phase I cancer patients with CCNE1 amplification: MD Anderson experiences. Sci. Rep, 2022.
6. Yap TA, Bessudo A, Hamilton E, Sachdev J, Patel MR, Rodon J, Evilevitch L, Duncan M, Guo W, Kumar S, Lu S, Dezube BJ, Gabrail N. IOLite: phase Ib trial of doublet/triplet combinations of dostarlimab with niraparib, carboplatin-paclitaxel, with or without bevacizumab in patients with advanced cancer. J Immunother Cancer, 2022.
7. Surana R, Rogers JE, Nogueras-Gonzalez GM, Hong DS, Yap TA, Rodon Ahnert J, Naing A, Wolff RA, Smalgo BG, Meric-Bernstam F, Subbiah V, Pant S. Prognostic factors associated with survival in patients with pancreatic cancer treated on early phase immune-checkpoint inhibitor clinical trials. ASCO Gastrointestinal Cancers Symposium, 2022.
8. Yap TA, Basu C, Goldman JW, Gordon M, Hamilton E, Kelly A, Liu F, Moreau AR, Neumann H, Papadopoulos K, Rugo HS, Shapiro GI, Vinayak S, Zhou L, Jhaveri K. A first-in-human phase 1/2a dose escalation/expansion study of the first-in-class CDK2/4/6 inhibitor PF‑06873600 alone or with endocrine therapy in patients with breast or ovarian cancer. San Antonio Breast Cancer Symposium (SABCS), 2021.
9. Kuplast-Barr K, Johnson M, Patel M, Yap T, Falchook G, LoRusso P, Abo R, Liu C, Manyak E, Cleary L, Bozon V, Parasuraman S, Keilhack H, McEachern K. RBN-2397, A Novel, Potent, And Selective Parp7 Inhibitor, Induces Tumor-Intrinsic Type I Interferon Responses and Adaptive Immunity In Preclinical Models And Patient Tumors. SITC Annual Meeting 2021, 2021.
10. Yap T, Barve M, Gainor J, Bockorny B, Ju Y, Cote S, Bilic S, Liu L, Chyung Y, Legler M, Gan L, McKean M. First-In-Human Phase 1 Trial Of SRK-181: A Latent TGFB1 Inhibitor, Alone Or In Combination With Anti-PD-(L)1 Treatment In Patients With Advanced Solid Tumors (Dragon Trial). SITC Annual Meeting 2021, 2021.
11. Ngoi NYL, Peng G, Yap TA. A Tale of Two Checkpoints: ATR Inhibition and PD-(L)1 Blockade, 2021.
12. Burton E, Ileana Dumbrava EE, Peng W, Milton D, Amaria R, Mcquade J, Glitza IC, Hong D, Patel S, Rodon J, Yap TA, Naing A, Piha-Paul SA, Balmes G, Lazar A, Meric-Bernstam F, Hwu P, Davies MA, Tawbi HA. Ph I/II study of PI3K-β inhibitor GSK2636771 (G771) in combination with pembrolizumab (P) in patients (pts) with PTEN loss and melanoma or other advanced solid tumors. ESMO Congress 2021, 2021.
13. Moyers J, Nguyen D, Hong DS, Ileana Dumbrava E, Fu S, Karp D, Naing A, Pant S, Janku F, Piha-Paul S, Rodon J, Subbiah V, Tsimberidou AM, Meric-Bernstam F, Yap TA. Adherence to the Food and Drug Administration (FDA) Guidance for the Co-Development of Two or More Investigational New Drugs in Phase 1/2 Cancer Trials. ESMO Congress 2021, 2021.
14. Papadopoulos K, Yap TA, Piha-Paul SA, Lorusso P, Hu-Lieskovan S, Shepherd CJ, Marshall S, Holz J, Poon E, Grabowska UB, Kayitalire L. A first-in-human phase I study of FS120, an OX40/CD137 tetravalent bispecific antibody, in patients with advanced malignancies. ESMO Congress 2021, 2021.
15. Saavedra Santa Gadea O, Greil R, de Jonge MJA, Tan D, Jerusalem G, Damien S, Grell P, Wainberg ZA, Wolf J, Joerger M, Carlino MS, Kasper S, Yap TA, Otero J, Yang X, Nesbitt V, Kim J, Ho Lee L, Choudhury S, Leal TA. Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with microsatellite stable (MSS) colorectal cancer (CRC). ESMO Congress 2021, 2021.
16. 1. Do KT, Chow LQM, Reckamp K, Sanborn RE, Burris H, Robert F, Camidge RD, Steuer CE, Strickler JH, Weise A, Specht JM, Gutierrez M, Haughney P, Hengel S, Derleth CL, Yap TA. First-in-Human, First-in-Class, Phase I Trial of the Fucosylation Inhibitors SGN-2FF in Patients with Advanced Solid Tumors, 2021.
17. Yap TA, Barve M, Gainor J, Weekes C, Bockorny B, Ju Y, Faucette R, Bilic S, Lee-Hoeflich S, Song G, Chyung Y, Legler M, Gan L, Bendell J. First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors. ASCO Annual Meeting 2021, 2021.
18. Yap TA, Tolcher A, Plummer E, Becker A, Fleuranceau-Morel P, Goddemeier T, Locatelli G, Gounaris I, De Bono J. A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors. ASCO Annual Meeting 2021, 2021.
19. Yap TA, Ashok A, Stoll J, Schwarzbach A, Blackwell K, Li T, Kang H, Garber J, Meric-Bernstam F. Rate of incidental germline findings detected by tumor-normal matched sequencing in cancer types lacking hereditary cancer testing guidelines. ASCO Annual Meeting 2021, 2021.
20. Falchook G, Patel M, Yap TA, McEachern K, Kuplast-Barr K, Utley L, Cleary L, Manyak E, Bozon V, Parasuraman S, Johnson M. A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors. ASCO Annual Meeting 2021, 2021.
21. Lynch R, Bendell J, Advani R, Falchook G, Munster P, Patel M, Gutierrez M, Burness M, Palmisiano N, Hamadani M, Bradley W, O'Shea T, Doleman S, Renschler M, Englert J, Yap TA. First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers. ASCO Annual Meeting 2021, 2021.
22. Zeineddine F, Garmezy B, Yap TA, Shen J. A more precise classifier of POLE mutations to identify candidates for immune therapy. ASCO Annual Meeting 2021, 2021.
23. Dumbrava E, Shapiro G, Bendell J, Yap TA, Jeselsohn R, Lepley D, Hurley S, Lin K, Liao M, Habeck J, Enke A, Hamilton E. Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors. ASCO Annual Meeting 2021, 2021.
24. Vo H, Fu S, Hong D, Karp D, Piha-Paul S, Subbiah V, Janku F, Naing A, Yap TA, Ahnert J, Ajani J, Cartwright C, Naqvi M, Nogueras-Gonzalez G, Miller V, Palmer G, Vining D, Berry D, Meric-Bernstam F, Tsimberidou A. Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT2): Challenges and Opportunities in Conducting an MD Anderson Randomized Study in Precision Oncology. ASCO Annual Meeting 2021, 2021.
25. Abo-Zahrah R, Karp D, Adat A, Yap TA, Fu S, Ahnert J, Piha-Paul S, Tsimberidou A, Naing A, Subbiah V, Dumbrava E, Overman M, Patel S, Amaria R, Westin S, Meric-Bernstam F, Janku F. Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progession in lymphatic nodes. ASCO Annual Meeting 2021, 2021.
26. Yap TA, Dumbrava EE, Rodon Ahnert J, Hong DS, Pant S, Karp DD, Piha-Paul SA, Subbiah V, Tsimberidou AM, Fu S, Janku F, Montez S, Ahmad-Taha MT, Guerrero D, Nazarenko NN, Moore Y, Soth M, Kovacs J, Heffernan TP, Jones P. First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors. ASCO Annual Meeting 2021, 2021.
27. Suzuki E, Molina J, Spencer ND, Bristow CA, Harris AL, Feng N, Mahendra M, Gera S, Soth MJ, Le K, Yap TA, Draetta G, Jones P, Heffernan TP, Kovacs JJ. The GLS1 inhibitor IPN60090 enhances antitumor immune response through metabolic reprogramming of T cells and impacts on the tumor microenvironment. AACR Annual Meeting 2021, 2021.
28. Kovacs JJ, Spencer ND, Bristow CA, Carugo A, Giluiani V, Miller MA, Harris AL, Feng N, Soth ML, Le K, De Stanchina E, Rudin CM, Draetta G, Yap TA, Jones P, Heffernan TP. Integrated approach towards defining mechanism based combinations to guide clinical development of glutaminase inhibitors. AACR Annual Meeting 2021, 2021.
29. Alhalabi O, Naing A, Groisberg R, Hahn A, Zhang S, Berkey SC, Tsimberidou AM, Rodon J, Yap TA, Pant S, Shah AY, Zurita-Saavedra A, Tannir N, Meric-Bernstam F, Subbiah V. Phase I study of mTORC1-2 inhibitor sapanisertib (TAK-228) in combination with carboplatin plus paclitaxelin patients with advanced solid malignancies and mTOR pathway alterations. AACR Annual Meeting 2021, 2021.
30. Johnson A, Ng PK, Kahle M, Castillo J, Amador B, Holla V, Vu T, Huang L, Su F, Kim S, Zeng J, Shufean MA, Conway T, Shaw KR, Yap TA, Rodon J, Meric-Bernstam F. Patient-specific, tiered, variant-level actionability correlates with functional effect in growth survival assay. AACR Annual Meeting 2021, 2021.
31. DiPeri TP, Evans KW, Tzeng CD, Kwong L, Kahle MP, Zheng X, Li D, Tran Cao HS, Vu T, Kim S, Su F, Kirby B, Wathoo C, Raso G, Rizvi Y, Wang H, Janku F, Shaw K, Yap T, Javle M, Rodon J, Meric-Bernstam F. The MD Anderson patient-derived xenograft series for modeling precision oncology in biliary tract cancers. AACR Annual Meeting 2021, 2021.
32. Spencer ND, Bristow CA, Guilani V, Miller MA, Carugo A, Harris AL, Minelli R, Feng N, Chang Q, Soth MJ, Le K, Weinstein JN, Lorenzi PL, Liu J, Wang W, Yap TA, Draetta G, Jones P, Heffernan TP, Kovacs JJ. Asparagine synthetase (ASNS) expression predicts response to the GLS1 inhibitor IPN60090 in ovarian cancer through selective modulation of redox homeostasis. AACR Annual Meeting 2021, 2021.
33. Yap TA. First-in-human phase 1 dose-escalation trial of the potent and selective next generation transforming growth factor-β receptor type 1 (TGF-βR1) inhibitor LY3200882 in patients with advanced cancers, 2018.
34. Yap TA. JAVELIN PARP Medley: a phase 1b/2 study of avelumab (anti–PD-L1) plus talazoparib in locally advanced or metastatic solid tumors. ESMO 2018 Congress, 2018.
35. Pilie PG, Peterson CB, Peng Y, Zhou L, Yap TA, Peng G, Jonasch E. Functional biomarkers of homologous repair (HR) deficiency to guide novel DNA damage response targeted therapy in clear cell renal cell carcinoma. ASCO 2018 Annual Meeting, 2018.
36. Yap TA, Burris HA, Kummar S, Falchook GS, Pachynski RK, LoRusso P, Tykodi SS, Gibney GT, Gainor JF, Rahma OE, Seiwert TY, Meric-Bernstam F, Blum Murphy MA, Keating Litton J, Diament Hooper EM, Hirsch HA, Harvey C, Clancy M, McClure T, Callahan MK. ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011 +/- nivolumab (nivo) in patients (pts) with advanced cancers. ASCO 2018 Annual Meeting, 2018.
37. Piha-Paul SA, Fu S, Hong DS, Janku F, Karp DD, Naing A, Pant S, Rodon Ahnert J, Subbiah V, Tsimberidou AM, Yap TA, Meric-Bernstam F. Phase I study of the pan-HER inhibitor neratinib given in combination with everolimus, palbociclib or trametinib in advanced cancer subjects with EGFR mutation/amplification, HER2 mutation/amplification or HER3/4 mutation. ASCO 2018 Annual Meeting, 2018.
38. Yap TA, Sahebjam S, Hong DS, Chiu VK, Yilmaz E, Efuni S, Grebennik DO, Collaku A, Ogunmefun E, Liu Y, Tayama T, Latek RR, Rixe O. First-in-human study of KHK2455, a long-acting, potent and selective indoleamine 2,3-dioxygenase 1 (IDO-1) inhibitor, in combination with mogamulizumab (Moga), an anti-CCR4 monoclonal antibody, in patients (pts) with advanced solid tumors. ASCO 2018 Annual Meeting, 2018.
39. Papadopoulos KP, Lakhani NJ, Johnson ML, Park H, Wang D, Yap TA, Moore KN, Sims TN, Emeremni C, Karasarides M, Kroog GS. A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody, in advanced cancers. ASCO 2018 Annual Meeting, 2018.
40. Kheder E, Hess KR, Xing Y, Cortez MA, Subbiah V, Janku F,Fu S, Naing A, Karp DD, Piha-Paul SA, Yap TA, Pant S, Rodon Ahnert J, Tawbi HA, Welsh JW, Meric-Bernstam F, Hong DS. TP53 mutations and programmed cell death ligand-1 expression in solid tumors: Associations with clinical factors and outcomes. ASCO 2018 Annual meeting, 2018.
41. Pant S, Subbiah V, Rodon J, Janku F, Hong DS, Karp D, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Savage RE, Chai F, Yu Y, Schwartz B, Meric-Bernstam F, Yap T. Results of a phase I dose escalation study of ARQ 751 in adult subjects with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations. AACR 2018 Annual Meeting, 2018.
42. Patnaik A, Bang Y-J, Chung HC, de Miguel Luken MJ, Yap TA, Hu L, Szpurka AM, Yu D, Chatterjee A, Nanda S, Vangerow B, Koneru M, Bendell J. Interim safety and clinical activity in patients (pts) with advanced refractory solid tumors from a phase Ia/b study investigating the novel anti-PD-L1 antibody (LY3300054) administered alone or in combination with other agents. AACR 2018 Annual Meeting, 2018.
43. Okeley NM, Heiser RA, Zeng W, Hengel SM, Wall J, Haughney PC, Yap TA, Robert F, Sanborn RE, Burris H, Chow LQM, Do KT, Gutierrez M, Reckamp K, Weise A, Camidge DR, Strickler J, Steuer C, Wang Z, O'Meara MM, Alley SC, Gardai SJ. SGN-2FF: A small-molecule inhibitor of fucosylation modulates immune cell activity in preclinical models and demonstrates pharmacodynamic activity in early phase 1 analysis. AACR 2018 Annual Meeting, 2018.
44. Michalarea V, Roda D, Drew Y, Carreira S, O’Carrigan BS, Shaw H, Roux R, Kumar S, Ward S, Parmar M, Turner A, Hall E, Serrano Fandos S, Perez R, Tunariu N, Raynaud F, Cullberg M, Foxley A, Lindemann JPO, Pass M, Rugman P, Lopez JS, Banerji U, Basu B, Plummer R, Kristeleit R, de Bono JS, Yap TA. Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations. 107th AACR Proceedings, 2016.
45. Yap TA, Winter JN, Leonard JP, Ribrag, V, Constantinidou A, Giulino-Roth L, Michot JM, Khan TA, Horner T, Carver J, Dumetrescu TP, He Z, McCabe MT, Creasy CL, Arindam Dhar A, Carpenter C, Johnson PM. A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2 (EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM). ASH 58th Annual Meeting 2016, 2016.
46. Yap TA, Krebs MG, Postel-Vinay S, Bang YJ, El-Khoueiry A, Abida W, Harrington K, Sundar R, Carter L, Castanon-Alvarez E, Im SA, Berges A, Khan M, Stephens C, Ross G, Soria JC. Phase I modular study of AZD6738, a novel oral, potent and selective ataxia telangiectasia Rad3-related (ATR) inhibitor in combination (combo) with carboplatin, olaparib or durvalumab in patients (pts) with advanced cancers. 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2016, 2016.
47. Billingham L, Dee Wherton D, Llewellyn L, Brown S, Johnson S, Fletcher P, Mulatero C, Yap TA, Summers Y, Spicer J, Sharpe R, Popat S, Middleton G. National Lung Matrix Trial: successful implementation of a phase II umbrella trial testing multiple genetic-marker-directed drugs in advanced non-small cell lung cancer. NCRI Cancer Conference 2016, 2016.
48. Ahmad Z, Fraser-Fish J, Kumar R, Ebbs B, Fowler G, Flohr P, Crespo M, Ahmad M, Popat S, Bhosle J, Banerji U, O'Brien M, de Bono J, Yap TA. Molecular characterization of PD-L1 status on circulating tumour cells (CTCs) isolated from patients with advanced cancers. NCRI Cancer Conference 2016, 2016.
49. Krebs MG, Spicer J, Steele JN, Talbot DC, Brada M, Wilson RH, Jones R, Basu B, Dawes JC, Parmar M, Purchase B, Turner AJ, Hall E, Tovey H, Banerji U, Yap TA. TAX-TORC: The Novel Combination of Weekly Paclitaxel and the Dual mTORC1/2 Inhibitor AZD2014 for the Treatment of Squamous NSCLC. 17th World Conference on Lung Cancer, 2016.
50. Sundar R, Custodio A, Lim J, Chenard-Poirier M, Collins D, Kaye S, Yap TA, Banerji U, Lopez J, De Bono JS. Clinical outcome of patients with advanced biliary tract cancer in a dedicated phase 1 unit. ESMO 2016 Congress, 2016.
51. Fraser-Fish J, Ahmad Z, Kumar R, Ebbs B, Fowler G, Flohr P, Crespo M, Ahmed M, Popat S, Bhosle J, Banerji U, O’Brien M, De Bono JS, Yap TA. Molecular characterization of PDL1 status of circulating tumor cells (CTCs) isolated with a novel label-free inertial microfluidic system from patients (pts) with advanced cancers. ESMO 2016 Congress, 2016.
52. Michalarea V, Constantinidou A, Guardascione M, Diamantis N, Perez R, Rihawi K, Geuna E, Lopez J, Kaye SB, Yap TA, De Bono JS, Banerji U, Molife LR, Tunariu N. Ultrasound guided biopsies in phase I trials: Single center experience of 350 consecutive cases. J Clin Oncol 34, 2016.
53. Coleman N, Michalarea V, Alken SP, Rihawi K, Greenwood K, Perez Lopez R, Tunariu N, Yap TA, Banerji U, De Bono JS, Welsh L, Molife LR, Saran F, Lopez J. Safety, efficacy and survival of patients (pts) with primary CNS tumors in phase 1 (Ph1) trials: A 12-year single institution experience. J Clin Oncol 34, 2016.
54. O'Carrigan B, de Miguel Luken MJ, Papadatos-Pastos D, Brown J, Tunariu N, Perez Lopez R, Ganegoda M, Riisnaes R, Figueiredo I, Carreira S, Hare B, Yang F, McDermott K, Penney MS, Pollard J, Lopez JS, Banerji U, De Bono JS, Fields SZ, Yap TA. Phase I trial of a first-in-class ATR inhibitor VX-970 as monotherapy (mono) or in combination (combo) with carboplatin (CP) incorporating pharmacodynamics (PD) studies. J Clin Oncol 34, 2016.
55. Diamantis N, Harris SJ, Constantinidou A, Vasiliki Michalarea V, Fontes MS, de Miguel Luken MJ, Avaiya TL, Petruckevitch A, Flohr D, Hanwell J, Papadatos-Pastos D, Lopez J, Yap TA, De Bono JS, Banerji U. Incidence, severity and factors associated with diarrhoea in phase I oncology studies: experience of 1002 consecutive cases. J Clin Oncol 34, 2016.
56. Gao FF, O'Brien M, Sarker,D Bhosle J, Yap TA, Uttenreuther-Fischer MM, Pemberton K, Goeldner RG, Wiebe S, De Bono JS, Spicer JF. A phase I study of afatinib combined with carboplatin or carboplatin plus paclitaxel in patients (pts) with advanced solid tumors. J Clin Oncol 34, 2016.
57. Harris SJ, de Miguel Luken MJ, Roda Perez D, Perez Lopez R, Parmar M, Prathapan V, Hassam H, Turner AJ, Serrano Fandos S, Hall E, Tovey H, Tunariu N, Lopez JS, Yap TA, De Bono JS, Banerji U. Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tumours. J Clin Oncol 34, 2016.
58. O'Carrigan B, Jalil A, Papadatos-Pastos D, Harris SJ, Lopez J, Banerji U, De Bono JS, Yap TA. Target-based therapeutic matching of phase I trials in patients with advanced breast cancer (BC pts) in the Royal Marsden Hospital Drug Development Unit (RMH DDU). J Clin Oncol 34, 2016.
59. Harris SJ, O'Carrigan B, Lopez SJ, Bhosle J, Banerji U, Popat S, De Bono JS, O'Brien MER, Yap TA. Clinical outcomes of advanced small cell lung cancer patients (SCLC pts) on phase I (Ph I) trials in the Drug Development Unit (DDU) at the Royal Marsden Hospital (RMH). J Clin Oncol 34, 2016.
60. Yap TA, Johnson PWM, Winter J, Leonard J, Giulino-Roth L, Horner T, Radswillas K, Carver J, Dhar A. A phase I, open-label study of GSK2816126, an enhancer of zeste homolog 2 (EZH2) inhibitor, in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), transformed follicular lymphoma (tFL), other non-Hodgkin’s lymphomas (NHL), multiple myeloma (MM) and solid tumor. J Clin Oncol 34, 2016.
61. Coker EA, Stewart A, Minchom A, O'Brien M, Yap TA, Workman P, Banerji U, Al-Lazikani B. SOCRATES: integrating ex vivo and in silico analysis to identify optimal drug combinations for patients. AACR 2016 Annual Meeting Proceedings, 2016.
62. Pollard J, Reaper P, Peek A, Hughes S, Gladwell S, Jones J, Chiu P, Wood M, Tolman C, Johnson M, Littlewood P, Penney M, McDermott K, Hare B, Fields SZ, Asmal M, O'Carrigan B, Yap TA. Defining optimal dose schedules for ATR inhibitors in combination with DNA damaging drugs: Informing clinical studies of VX-970, the first-in-class ATR inhibitor. AACR 2016 Annual Meeting Proceedings, 2016.
63. Stewart A, Coker E, Minchom A, Thavasu P, Georgiou A, Sadanandam A, Yap TA, de Bono JS, Al-Lazikani B, Banerji U. KRAS and clinical context: Differential dynamic signaling output of KRAS mutant lung, colorectal and pancreatic cancer cell lines when exposed to targeted anticancer drugs. AACR 2016 Annual Meeting Proceedings, 2016.
64. Ahmad Z, Fraser-Fish J, Kumar R, Ebbs B, Fowler G, Flohr P, Crespo M, Popat S, Bhosle J, Banerji U, O'Brien M, de Bono JS, Yap TA. Characterization of PD-L1 expression on circulating tumor cells (CTCs) isolated with a label-free inertial microfluidic system from advanced non-small cell lung cancer patients (NSCLC pts). AACR 2016 Annual Meeting Proceedings, 2016.
65. Shapiro G, Wesolowski R, Middleton M, Devoe C, Constantinidou A, Papadatos-Pastos D, Fricano M, Zhang Y, Karan S, Pollard J, Penney M, Asmal M, Renshaw FG, Fields SZ, Yap TA. Phase 1 trial of first-in-class ATR inhibitor VX-970 in combination with cisplatin (Cis) in patients (pts) with advanced solid tumors (NCT02157792). AACR 2016 Annual Meeting Proceedings, 2016.
66. Middleton G, Popat S, Walker I, Mulatero C, Spicer J, Summers Y, Yap TA, Crack LR, Billingham LJ.. The National Lung Matrix Trial: Multi-Drug, Genetic Marker-Directed, Multi-Arm Phase II Trial in Non-Small Cell Lung Cancer IASLC. IASLC. e-Pub 2015.
67. Papadatos-Pastos D, Roda D, De Miguel Luken MJ, Michalarea V, Lima J, Diamantis N, Capelan M, Jalil A, Bodla S, Bhosle J, Molife R, O’Brien M, Banerji U, Popat S, Yap TA. Clinical outcome and prognostic factors for advanced malignant mesothelioma (MM) patients (pts) treated on phase I trials. IASLC 2015. e-Pub 2015.
68. Michalarea V, Lopez J, Lorente D, Carreira S, Hassam H. Parmar M, Turner A, Hall E, Serrano Fandos S, Decordova S, Swales K, Ruddle R, Raynaud F, Tunariu N, Stephens CM, Molife LR, Banerji U, Plummer R, De Bono J, Yap TA. Translational phase I trial combining the AKT inhibitor AZD5363 and PARP inhibitor Olaparib in advanced cancer patients. Eur J Cancer, Abstracts form the European Cancer Congress 2015 51(Suppl 3), 2015.
69. Papadatos-Pastos D, Roda D, De Miguel Luken M, Jalil A, Diamantis N, Michalarea V, Lima J, Capelan M, Bodla S, Bhosle J, Molife R, O’Brien M. Banerji U, Popat S. Yap T. Clinical outcome and prognostic factors of patients (pts) with relapsed mesothelioma on phase I trials in the Drug Development Unit of the Royal Marsden Hospital. Eur J Cancer, Abstracts form the European Cancer Congress 2015 51(Suppl 3), 2015.
70. Rafii S, Gourley C, Ang JE, Kumar R, Geuna E, Rye T, Ashcroft L, Powell B, Shapira-Frommer R, Friedlander M, Chen LM, Matulonis U, Kaufman B, De Greve J, Oza AM, Banerjee S, Gore ME, Molife LR, Kaye SB, Yap TA. What clinical factors influence advanced BRCA1/2 mutant ovarian cancer patient outcomes to poly(ADP-ribose) polymerase inhibitor treatment?. J Clin Oncol 33(15s), 2015.
71. George A, Michalarea V, Rafii S, Michie CO, Wong M, Bowen R, Han LY, Rallis G, Banerji U, Kristeleit R, de Bono JS, Banerjee S, Gore M, Kaye SB, Yap TA. Clinical outcomes in advanced cervical cancer (CC) and endometrial cancer (EC) patients (pts) treated in phase I trials of novel molecularly targeted agents (MTAs). J Clin Oncol 33(15S), 2015.
72. 29. Michalarea V, de Miguel Luken MJ, Diamantis N, Garg A, Maubon L, Yap TA, Molife LR, de Bono JS, Ursell P, Banerji U. Ocular toxicity with MEK inhibitors in phase I trials: A single centre experience across six clinical trials. J Clin Oncol 33(15S), 2015.
73. de Miguel Luken MJ, Roda D, Perez Lopez R, Jimenez B, Hassam H, Sathiyayogan N, Parmar M, Turner AJ, Hall E, Tunariu N, Molife LR, Yap TA, de Bono JS, Banerji U. A pharmacokinetic and pharmacodynamic biomarker-driven phase I study of intermittent, low dose intensity schedules of the dual MEK/RAF inhibitor, RO5126766 in patients with advanced solid tumors 33(15S), 2015.
74. Papadatos-Pastos D, Kumar R, Yap TA, Ruddle R, Decordova S, Jones P, Halbert G, Garrett MD, McLeod R, Backholer Z, Swales KE, Raynaud FI, de Bono JS, Banerji U. A first-in-human study of the dual ROCK I/II inhibitor, AT13148, in patients with advanced cancers. J Clin Oncol 33(15S), 2015.
75. Michalarea V, Lorente D, Lopez J, Carreira S, Hassam H, Parmar M, Sathiyayogan N, Turner A, Hall E, Serrano Fandos S, Seeramreddi S, Decordova S, Swales K, Ruddle R, Raynaud F, Tunariu N, Attard G, Molife LR, Banerji U, Plummer R, de Bono JS, Yap TA. Accelerated phase I trial of two schedules of the combination of the PARP inhibitor olaparib and AKT inhibitor AZD5363 using a novel intrapatient dose escalation design in advanced cancer patients. Cancer Res 75(15 Suppl), 2015.
76. Thavasu P, Wong AC, Jimenez B, Basu B, Turner A, Hall E, Yap TA, Banerjee S, Leach M, de Bono JS, Chung YL, Banerji U. Translating preclinical observations to the clinic: Combination of the dual m-TORC1/2 inhibitor AZD2014 and paclitaxel in ovarian and lung cancer. Cancer Res 75(15 Suppl), 2015.
77. Yap T, Williamson S, Beggs A, Creedon H. Hargreaves C, Norris L, Richman S, Romero D, Roxburgh T, Savage K, Turkington R, Walter H, Fairbairn E. Training the next generation of cancer research leaders: development of the Experimental Cancer Medicines Centers (ECMC) Junior Investigator Network Group (JING). NCRI Cancer Conference. e-Pub 2014.
78. Yap TA, Ahmad Z, Fraser-Fish J, de Bono JS. Assessment and validation of a novel high throughput label-free microfluidic-based circulating tumor cell (CTC) platform. Prostate Cancer Foundation Annual Retreat. e-Pub 2014.
79. Kumar R, Mateo J, Smith A, Khan K, Ruddle R, Swales K, Decordova S, Backholer Z, Jones P, Tran C, Seeramreddi S, McLeod R, Yap TA, Raynaud F, Garrett M, Banerji U. TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors. J Clin Oncol 32(15S), 2014.
80. Roda D, Wong HH, Geuna E, Rafii S, Ruddle R, Hayes A, Swales K, Stimpson S, Sathiyayogan N, Tunariu N, Turner A, Hall E, Yap TA, Banerjee S, O'Brien M, Molife LR, Kaye S, de Bono J, Basu B, Banerji U. TAX-TORC: A phase I trial of the combination of AZD2014 (dual mTORC1/mTORC2 inhibitor) and weekly paclitaxel in patients with solid tumors. J Clin Oncol 32(15S), 2014.
81. Geuna E, Roda D, Rafii S, Jimenez B, Capelan M, Rihawi K, Yap TA, Kaye S, de Bono JS, Molife LR, Banerji U. Complications of hyperglycemia in phase 1 trials targeting the PI3K-AKT-mTOR pathway. J Clin Oncol 32(15S), 2014.
82. Rafii S, Roda D, Geuna E, Jimenez B, Rihawi K, Capelan M, Yap TA, Kaye S, Molife LR, de Bono J, Banerji U. A study of risk of infection with drugs targeting the PI3K, AKT, and mTOR pathway. J Clin Oncol 32(15S), 2014.
83. Frenel JS, Carreira S, Goodall J, Roda D, Smith A, Mateo J, Ong M, Gasi-Tandefelt D, Yap TA, Attard G, Figueiredo I, Rodrigues D, Flohr P, Molife LR, Kaye SB, Banerji U, de Bono SB. Targeted deep sequencing from circulating plasma DNA as a multipurpose biomarker in patients referred for phase I trials. J Clin Oncol 32(15S), 2014.
84. Frenel J, Carreira S, Goodall J, Roda-Perez D, Smith A, Mateo J, Ong M, Gasi-Tandefelt D, Yap TA, Attard G,Nava-Rodrigues D ,Molife LR, Kaye, S, Banerji U, de Bono J. Serial next generation sequencing of cfDNA to monitor phase I targeted drug administration. Ann Oncol 25(Suppl 4), 2014.
85. Basu B, Roda-Perez D, Wong H, Sathiyayogan N, Parmar M, Turner A, Swales K, Stimpson S, Hall E, Hategan M, Garcia-Corbacho J, Yap TA, Molife LR, Jimenez B, Banerjee S, Kaye S, de Bono J, Banerji U. Phase I multicentre TAX-TORC trial of the dual mTORC1/2 inhibitor AZD2014 (A) plus weekly paclitaxel (P) in patients (pts) with solid tumours (CRUKD/12-013). Ann Oncol 25(Suppl 4), 2014.
86. Capelan M, Roda D, Geuna E, Rihawi K, Shankar B, Kaye SB, Bhosle J, Molife LR, Banerji U, O´Brien M, de Bono JS, Popat S, Yap TA. Clinical outcome of advanced non-small cell lung cancer patients (ANSCLC pts) on phase I trials in the drug development unit (DDU) at the Royal Marsden Hosptial (RMH). Ann Oncol 25(Suppl 4), 2014.
87. Yap TA, George A, Michie C, Wong M, Bowen R, Rafii S, Michalarea V, van Hagen T, Han L, Rallis G, Molife LR, Banerji U, Kristeleit R, Banerjee S, de Bono JS, Gore ME, Kaye SB. What factors influence advanced ovarian cancer patient outcomes to phase I trial treatments?. J Clin Oncol 32(15S), 2014.
88. Mateo J, De Bono JS, Ramanathan RK, Lustberg MB, Zivi A, Basset D, Ng M, Young A, Garrett M, Decordova S, Raynaud F, Yap TA, Zukiwski AA, Proniuk S, Shapiro CL. A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with solid tumors. J Clin Oncol 31(15S), 2013.
89. Khan KH, Young A, Mateo J, Tunariu N, Yap TA, Tan D, Mansfield D, Wong M, Riisnaes R, Harrington KJ, De Bono JS. Phase I clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging. J Clin Oncol 31(15S), 2013.
90. Mateo J, Ong M, Pope L, Cassidy AM, Yap TA, Perkins G, Riisnaes R, Flohr P, Thway K, Gonzalez M, Saeed S, Young AM, Toloui HN, Khan K, Moran K, Ng M, Molife LR, Banerji U, Kaye SB, de Bono JS. Correlation of oncogenic mutations in circulating cell-free DNA (cfDNA) and tumor tissue through a multiplex sequencing platform in patients under consideration for phase I trials. J Clin Oncol 30(15S), 2012.
91. Ong M, Mateo J, Pope L, Cassidy AM, Yap TA, Perkins G, Riisnaes R, Flohr P, Thway K, Saeed S, Denholm KA, Jaime JC, Biondo A, Molife LR, Kaye SB, Banerji U, de Bono JS. Prospective study of oncogenic mutations in circulating cell-free DNA (cfDNA) using a multiplex sequencing platform for patient (pt) allocation to phase I clinical trials. J Clin Oncol 30(15S), 2012.
92. Ang JE, Gourley C, High HA, Shapira-Frommer R, Powell CB, Castonguay V, de Greve J, Yap TA, Fong PC, Olmos D, Banerjee SN, Chen LM, Friedlander M, Kaufman B, Oza AM, de Bono JS, Gore ME, Kaye SB. Use of chemotherapy (CT) in BRCA1/2-deficient ovarian cancer (BDOC) patients (pts) with poly-ADP-ribose polymerase inhibitor (PARPi) resistance: A multi-institutional study. J Clin Oncol 30(15S), 2012.
93. Jaime JC, Young AM, Mateo J, Yap TA, Denholm KA, Shah KJ, Tunariu N, Sassi S, Karapanegiotou L, Mansfield D, Molife LR, Harrington KJ, de Bono JS. Phase I clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging. J Clin Oncol, 2012.
94. Yap TA, Walton MI, Grimshaw KM, te Poele RH, Eve PD, Valenti MR, de Haven Brandon AK, Martins V, Zetterlund A, Heaton SP, Heinzmann K, Jones PS, Feltell RE, Reule M, Woodhead SJ, Davies TG, Lyons JF, Raynaud FI, Eccles SA, Workman P, Thompson NT, Garrett MD. The novel clinical candidate AT13148 is an oral multi-ACG kinase inhibitor with potent pharmacodynamic and antitumor activity and demonstrates a mechanism of action distinct from AKT inhibitors. Cancer Res, AACR 103 Annual Meeting Proceedings 72(8 Suppl), 2012.
95. Biondo A, Pedersen JV, Karapanagiotou EM, Tunariu N, Mansfield D, Sassi S, Corral J, Yap TA, Harrington KJ, de Bono JS. Phase I Clinical Trial of a Genetically Modified Oncolytic Vaccinia Virus GL-ONC1 With Green Fluorescent Protein Imaging. Eur J Cancer 47(S162), 2011.
96. Yap TA. Yan L, Patnaik A, Olmos D, Fearen I, Baird RD, Papadopoulos KP, Tunariu N, Biondo A, Keilhack H, Delgado LM, Taylor A, Blackman SC, Carpenter CL, Decordova S, Heaton S, Garrett MD, Sullivan D, De Bono JS and Tolcher W. Final results of a translational phase l study assessing a QOD schedule of the potent AKT inhibitor MK-2206 incorporating predictive, pharmacodynamic (PD), and functional imaging biomarkers. J Clin Oncol 29(15S), 2011.
97. Tan DSP, Yap TA, Hutka MM, Roxburgh P, Grzybowska E, Gourley C, Gore ME, Kaye SB. Implications of BRCA1 and BRCA2 mutations on taxane sensitivity in patients (pts) with advanced ovarian cancer. J Clin Oncol 29(15S), 2011.
98. Pedersen JV, Karapanagiotou EM, Biondo A, Tunariu N, Puglisi M, Denholm KA, Sassi S, Mansfield D, Yap TA, de Bono JS, Harrington KJ. A phase I clinical trial of a genetically modified and imageable oncolytic vaccinia virus GL-ONC1 with clinical green fluorescent protein (GFP) imaging. J Clin Oncol 29(15S), 2011.
99. Perkins G, Dukes J, Pope L, Clark J, Yap TA, Riisnaes R, Cassidy A, Kaye SB, de Bono JS. Prospective study of genetic mutations in matched tumor and plasma specimens in advanced cancer patients referred to phase I trials. Cancer Res 71(8 Suppl), 2011.
100. Yap TA, Perkins G, Dukes J, Riisnaes R, Pope L, Cassidy A, Denholm KA, Gonzalez de Castro DG, Chau I, de Bono JS.. Prospective study of genetic mutations in matched tumor and plasma specimens in colorectal cancer patients. J Clin Oncol 29(4_suppl), 2011.
101. Yap TA, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Tunariu N, Sullivan D, Yan L, de Bono JS, Tolcher AW. A translational biomarker study of MK2206 (MK), a potent allosteric AKT inhibitor demonstrating profound target and pathway inhibition. ASCO-NCI-EORTC 2010 Molecular Markers in Cancer, 2010.
102. Sandhu S, Massard C, Papadatospastos D, Yap T, Olmos D, Baird R, de Bono JS. Baseline circulating tumor cell (CTC) counts enhance the performance of the Royal Marsden Hospital (RMH) prognostic score and improve patient selection for phase 1 clinical trials. Eur J Cancer 7(Supplements 8):189-190, 2010.
103. Pederson JV, Karapanagiotou L, Alam S, Puglisi M, Britton L, Sassi S, Mansfield D, Yap T, De-Bono J, Harrington K. Preliminary results of a Phase 1 study of intravenous administration of GL-ONC1 Vaccinia virus in patients with advanced solid cancer with real time imaging. NCRI Meeting. e-Pub 2010.
104. Papadatos-Pastos D, Baird R, Olmos d, Sandhu S, Massard C, Dukes J, Pope L, Grainger P, Yap T, De-Bono, J.. Baseline circulating tumour cell (CTC) counts enhance the performance of the Royal Marsden Hospital (RMH) prognostic score to optimize patient selection for phase 1 clinical trials. NCRI Cancer Conference. e-Pub 2010.
105. Pedersen JV, Karapanagiotou L, Alam S, Puglisi M, D Mansfield, Yap TA, de Bono JS, Harrington K. Preliminary results of a phase 1 study of intravenous administration of GL-ONC1 Vaccinia virus including green-fluorescent protein real time imaging in patients with advanced cancer. Eur J Cancer 7(Supplements 8):23, 2010.
106. Ang J, Yap TA, Fong P, Carden C, Tan DS, Carmichael J, de Bono JS, Gore M, Kaye SB. Preliminary experience with the use of chemotherapy following treatment with olaparib, a poly(ADP-ribose) polymerase inhibitor, in patients with BRCA1/2-deficient ovarian cancer. J Clin Oncol 28(15s), 2010.
107. Yap TA, Patnaik A, Fearen I, Olmos D, Papadopoulos K, Tunariu N, Sullivan D, Yan L, de Bono JS, Tolcher AW. First-in-class phase I trial of a selective Akt inhibitor, MK2206, evaluating alternate day and once weekly doses in advanced cancer patients with evidence of target modulation and antitumor activity. J Clin Oncol 29(15S), 2010.
108. Yap TA, Walton MI, Hunter LK, Grimshaw K, Valenti M, Eve P, Pickard L, Heaton S, Caldwell JJ, Thompson N, de Bono J, Kaye S, Eccles SA, Workman P, Collins I, Garrett MD. First report of preclinical pharmacology of two novel potent AKT inhibitors and development of pharmacodynamic biomarkers in tumor and surrogate tissue. AACR; Cancer Res 70(8 Suppl), 2010.
109. |Yap TA, Walton MI, Hunter LK, Grimshaw K, Valenti M, Eve P, Pickard L, Heaton S, Caldwell JJ, Thompson N, de Bono J, Kaye S, Eccles SA, Workman P, Collins I, Garrett MD. First report of preclinical pharmacology of two novel potent AKT inhibitors and development of pharmacodynamic biomarkers in tumor and surrogate tissue. AACR; Cancer Res 70(8 Suppl), 2010.
110. Yap TA, Papadopoulos K, Fearen I, Carpenter C, Delgado L, Taylor A, Olmos D, Brunetto A, Tall M, Decordova S, Walton MI, Heaton SP, Garrett MD, Domsch J, Patnaik A, Sullivan D, Yan L, de Bono JS, Tolcher AW. First dose-finding study in cancer patients (pts) of a potent, selective, allosteric AKT inhibitor MK2206 (MK), incorporating pharmacodynamic (PD) and predictive biomarkers and showing profound pathway blockade. Cancer Res 70(8 Suppl), 2010.
111. Tan D, Lolkema M, Harrington K, Forster M, Evans J, Arkenau HT, Roxburgh P, Morrison R, Kapawa J, Roulstone V, Coffey M, Alam S, Brunetto A, Yap TA, Mettinger K, de Bono JS. A phase-I study of the combination of intravenous reovirus (REOLYSIN) and gemcitabine in patients with advanced cancer. NCRI Cancer Conference. e-Pub 2009.
112. Forster M, Olmos D, Frentzas S, Sandhu S, Yap TA, Tan D, Barriuso J, Wright M, Morris Groves M, Reardon D, Curtis M, Hodge J, Suttle B, Ma B, Lager J, de Bono JS. Pazopanib and lapatinib in patients with relapsed malignant glioma: Phase I/II study. NCRI Cancer Conference. e-Pub 2009.
113. Alam S, Carden C, Langham M, Frentzas S, Dolly S, Sandhu S, Kristeleit R, Yap TA, Casamayor I, Matthews T, Stephens AW, Poondru S, Kim E, Kaye SB. Preliminary activity in adrenocortical tumour (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small molecule insulin like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumours. NCRI Cancer Conference. e-Pub 2009.
114. Brunetto AT, Kristeleit R, Tan D, Yap TA, Alam S, Dolly S, Olmos D, Fong P, Molife R, Harris T, Van Besterveldt L, Fourneau N, Hellemans P, De-Bono JS, Venugopal B, Evans J. A first in human phase I study of JNJ26481585, a novel oral histone deacetylase inhibitor (HDACi), in patients with advanced solid tumours: early evidence of anti-tumour activity. NCRI Cancer Conference. e-Pub 2009.
115. Sandhu S, Yap TA, Tunariu N, Lolkema M, Tan DS, Brunetto AT, Kristeleit R, Alam S, Molife R, Kapawa J, Germuska M, Garmey E, Chai F, Li J, Kaye SB, deSouza N, de Bono JS. Pharmacokinetic and pharmacodynamic phase I trial of ARQ197 incorporating dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) studies investigating the antiangiogenic activity of selective c-Met inhibition. NCRI Cancer Conference. e-Pub 2009.
116. Yap TA, Alam S, Lolkema M, Tan DS, Forster M, Dolly S, Carden CP, Sandhu S, Fong P, Little A, Patnaik A, Papadopoulos K, Tromp B, Puchalski T, Berns B, Tolcher A, de Bono JS. First-in-man, pharmacokinetic and pharmacodynamic phase I trial of a human monoclonal antibody CNTO888 to CC-Chemokine Ligand 2 (CCL2/MCP-1) in patients with solid tumours. NCRI Cancer Conference. e-Pub 2009.
117. Yap TA, Papadopoulos K, Fearen I, Carpenter C, Delgado L, Taylor A, Domsch J, Olmos D, Brunetto A, Tan DD, Decordova S, Heaton SP, Garrett MD, Patnaik A, Sullivan D, Yan L, de Bono JS, Tolcher AW. First-in-man, first-in-class phase I study of two schedules of MK-2206, a novel oral Akt inhibitor, in patients (pts) with advanced solid tumors, including ovarian and castration resistant prostate cancer (CRPC). Mol Cancer Ther 8(12 Suppl), 2009.
118. Brunetto AT, Tan DSW, Olmos D, Yap TA, Frentzas, Sandhu S, K Denholm, Ayite B, de Bono JS, Kaye S. Changing perceptions of oncologists referring advanced colorectal (ACRC) patients (pts) to phase 1 trials: an evidence based approach. Joint ECCO 15-34th ESMO Multidisciplinary Congress. Eur J Cancer 7(2 suppl), 2009.
119. Yap TA, Lolkema M, Tunariu N, Brunetto A, Germuska M, Garmey E, deSouza N, de Bono J. Pharmacokinetic and pharmacodynamic Phase I trial of ARQ 197 incorporating dynamic contrast-enhanced and diffusion weighted magnetic resonance imaging studies investigating the antiangiogenic and antitumor activity of selective c-Met inhibition. Joint ECCO 15-34th ESMO Multidisciplinary Congress. Eur J Cancer 7(2 suppl), 2009.
120. Tan D, Brunetto A, Ang J, Olmos D, Frentzas S, Arkenau H, Yap TA, de Bono JS, Kaye SB. Unplanned hospital admissions as an early surrogate indicator of patient attrition in phase I trials. J Clin Oncol 27(15s), 2009.
121. George S, Lal R, Camidge R, Arkenau H, Chick J, Yap TA. Final results of a dose escalation, pharmacokinetic, and pharmacodynamic study of two schedules of OSI-930 in patients with advanced solid tumors. J Clin Oncol 27(15s), 2009.
122. Tolcher AW, Yap TA, Fearen I, Taylor A, Carpenter C, Papadopoulos K, Yan L, de Bono JS. Phase I study of MK-2206 an oral potent allosteric Akt inhibitor in patients with advanced solid tumors. J Clin Oncol 27(15s), 2009.
123. Yap TA, Frentzas S, Tunariu N, Barriuso J, Waghorne C, deSouza N, de Bono JS. Final results of a pharmacokinetic and pharmacodynamic phase I trial of ARQ 197 incorporating dynamic contrast-enhanced magnetic resonance imaging studies investigating the antiangiogenic activity of selective c-Met inhibition. J Clin Oncol 27(15s), 2009.
124. Lau A, McCormack P, Magena R, Goboriau D, Knights C, Unwin L,Wu P, Cranston A, Boss D, Mergui-Roelvink M, Fong PC, Yap TA, Ashworth A, Kaye SB, Schellens J, De Bono J, Carmichael, Tutt A, Swaisland H, O'Connor MJ. A pharmacodynamic (PD) evaluation of the PARP inhibitor olaparib (AZD2281) in a first-in-human Phase I trial of patients with advanced solid tumours. 100th AACR Annual Meeting Proceedings, Cancer Res 69, 2009.
125. Yap TA, Barriuso J, Frentzas S, Riisnaes R, Clark J, Moreira J, Wright M, Futreal A, Savage R, Chan T, Chai F, de Bono J. Phase I trial of an oral c-Met inhibitor ARQ197, which inhibits tumour c-Met and FAK phosphorylation and has reached maximum tolerated dose in a twice daily dosing schedule. NCRI Cancer Conference, 2008.
126. Raynaud FI, Martins V, Yap TA, Carden C, Jones RL, Riggs SB, Lee G, de Bono JS. Comparative pharmacokinetic study of abiraterone acetate in a capsule and tablet formulation. Eur J Cancer 6(S12), 2008.
127. Yap TA, Barriuso J, Frentzas S, Riisnaes R, Clark J, Dukes J, Futreal A, R, Chai F, de Bono JS. Pharmacokinetic and pharmacodynamic phase I study of an oral c-Met inhibitor ARQ197 reaches maximum tolerated dose in a twice daily dosing schedule. Eur J Cancer 6(S12), 2008.
128. Boss D, Fong P, Yap TA, Tutt A, Carmichael J, O’Connor M, Schellens J, de Bono J. First in human phase I study of AZD2281, a small molecule inhibitor of PARP. European Assoc for Clin Pharm & Therapeutics (EACPT) Congress, 2008.
129. de Bono JS, Attard G, Reid A, Parker C, Dowsett M, Molife R, Yap TA, Molina A, Lee G, Dearnaley D. Anti-tumor activity of abiraterone acetate, a CYP17 inhibitor of androgen synthesis, in chemotherapy naive and docetaxel pre-treated castration resistant prostate cancer. J Clin Oncol 26(15S), 2008.
130. Yap TA, Harris D, Barriuso J, Wright M, Riisnaes R, Ledaki I, Savage R, de Bono JS. Phase I trial to determine the dose range for the c-Met inhibitor ARQ 197 that inhibits c-Met and FAK phosphorylation, when administered by an oral twice-a-day schedule. J Clin Oncol 26(15S), 2008.
131. Attard G, Reid A,Yap TA, Folkerd E, Clark J, Cooper C, Dowsett M, Lee G, de Bono JS. Predictors of response and pharmacodynamic endpoints in a phase I and pharmacokinetic study of abiraterone acetate in castration-resistant prostate cancer. ASCO Genitourinary Cancers Symposium, 2008.
132. Attard G, Reid A, Yap TA, Molife R, Sinha R, Barrett M, Parker C, Dearnaley D, Raynaud F, Folkerd E, Dowsett M, Lee G, de Bono J. Inhibition of androgen synthesis by selective inhibition of CYP450c17 results in a high response rate in castration-resistant prostate cancer. NCRI Cancer Conference. e-Pub 2007.
133. Fong PC, Boss D, Yap TA, Tutt A, Kaye SB, Schellens JH, de Bono JS. A Phase I trial of AZD2281 (KU-0059436), a PARP inhibitor with single agent anticancer activity in patients with BRCA deficient tumours, particularly ovarian cancer. NCRI Cancer Conference. e-Pub 2007.
134. Reid AH, Tang A, Spicer J, Gallerani E, Mears D, Shaw H, Karavasilis V, Settatree S, Yap TA, Marriot M, Puchalski TA, Harrison M, Naish J, Mann H, de Bono JS. An exploration of the ability of DCE-CT scans to evaluate blood flow in an open, pharmacokinetic (PK) and mass balance study of 14[C]-cediranib. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. Mol Cancer Ther 6(11 Suppl), 2007.
135. Molife R, Lee J, Petrylak D, Blumenschein, G, Lassen U, Clark J, Yap T, Rowen E, Ang J, Crowley E, Clarke A, Hawthorne T, Buhl-Jensen P, de Bono J, Kelly K. A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. Mol Cancer Ther 6(11 Suppl), 2007.
136. Shaw HM, Molife R, Karavasilis V, Ong T, Tate L, Fong PC, Yap TA, Christensen O, de Bono JS. A Phase Ib study of telatinib (BAY 57-9352), a VEGFR-2 inhibitor, in combination with docetaxel in patients with advanced solid tumors. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications. Mol Cancer Ther 6(11 Suppl), 2007.
137. Olmos D, Molife R, Okuno S, Worden F, Hammer G, Yap TA, Shaw H, Schuetze S, Roberts L, Gualberto A, de Bono J, and Haluska P. Safety, tolerability and preliminary efficacy of the anti-IGF-IR monoclonal antibody CP-751,871 in patients with sarcomas and adrenocortical tumors 6(11 Suppl), 2007.
138. Attard G, Reid A, Sinha R, Molife R, Raynaud F, Dowsett M, Barrett M, Thompson E, Yap TA, Settatree S, Martins V, Parker C, Dearnaley D, Folkerd E, Lee G, de Bono JS 6(11 Suppl), 2007.
139. Yap TA, Boss DS, Fong P, Tutt A, Carmichael J, O’Connor MJ, Kaye SB, Schellens J, de Bono JS. First in human phase I PK and PD study of KU-0059436, an inhibitor of Poly ADP-Ribose Polymerase (PARP) in cancer patients, including BRCA1/2 mutation carriers. J Clin Oncol 25(18S), 2007.
140. Reid AH, Tang A, Spicer J, Gallerani E, Settatree S, Yap TA, Harrison M, de Bono J. An open, PK and mass balance study of 14C-AZD2171, incorporating DCE-CT evaluations. J Clin Oncol, 2007.
141. Haluska P, Shaw H, Molife L, Adjei AA, Yap TA, Roberts ML, Gualberto A, de Bono JS. Phase I dose escalation study of the anti-IGF-1R monoclonal antibody CP-751,871 in patients with refractory solid tumors. J Clin Oncol 25(18S), 2007.
142. Spicer JF, Vidal L, Pandha H, Yap T, White C, Coffey M, Kaye S, Harrington K, de Bono J. Final results of a phase I study of wild-type oncolytic reovirus in patients with advanced cancer. J Clin Oncol, 2007.
143. Kelly WK, Yap T, Lee J, Lassen U, Crowley E, Hawthorne T, Buhl-Jensen P, de Bono J. A phase I study of oral belinostat (PXD101) in patients with advanced solid tumors, 2007.
144. Gallerani E, Yap TA, Lopez A, de las Heras B, Cortes-Funes H, de Bono J, Paz-Ares L. Phase I study of PM00104, a novel cytotoxic anti-cancer drug, administered to patients with advanced solid tumors or lymphoma. J Clin Oncol 25(18S), 2007.
145. Attard G, Yap TA, Reid A, Settatree S, Parker C, Raynaud F, Dowsett M, Dearnaley D, de Bono JS. Phase I study of continuous oral dosing of an irreversible CYP450c17 inhibitor, Abiraterone, in castration refractory prostate cancer patients. J Clin Oncol 25(18S), 2007.
146. Yap TA, Attard G, Reid A, Raynaud F, Dowsett M, Dearnaley D, de Bono JS. Abiraterone acetate, an oral irreversible inhibitor of CYP450c17, administered to castration refractory prostate cancer patients is safe and has a high degree of durable antitumor activity. American Urological Association Annual Meeting, 2007.
147. de Bono J, Boss D, Fong P, Roelvink M, Yap TA, Tutt A, Mortimer P, O’Connor M, Schellens J, Kaye S. First in human Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of KU-0059436, a small molecule inhibitor of poly ADP-RIBOSE polymerase (PARP) in cancer patients (P), including BRCA 1/2 mutation carriers. 5th International Symposium on Targeted Anticancer Therapies (TAT). Ann Oncol 18(4 suppl):26-27, 2007.
148. Attard G, Yap TA, Reid A, Parker C, Barrett M, Raynaud F, Dowsett M, Dearnaley D, Lee G, de Bono JS. Activity, toxicity, and effect on steroid precursor levels of abiraterone, an oral irreversible inhibitor of CYP17, in castration refractory prostate cancer. ASCO Prostate Cancer Symposium, 2007.
149. de Bono JS, Attard G, Reid A, Yap TA, Barrett M, Molife R, Parker C, Raynaud F, Dowsett M, Folkerd L, Lee G, Dearnaley D. Abiraterone administered to castration resistant prostate cancer (CRPC) patients is well tolerated and has a high level of antitumor efficacy. AACR Innovations in Prostate Cancer Research Conference, 2006.
150. Fong P, Molife R, Attard G, Yap TA, Vidal L, Digue L, Karavasilis V, Gualberto A, de Bono J.. Phase I trial incorporating circulating tumour cells of CP-751,871, a monoclonal antibody against the insulin-like growth factor 1 receptor with docetaxel in cancer patients. Eur J Cancer 4(12S), 2006.
151. de Bono JS, Boss D, Fong P, Roelvink M, Yap TA, Tutt A, O’Connor M, Schellens J, Kaye S. Phase I evaluation of an inhibitor of PARP, KU-0059436 in patients with advanced tumours. Eur J Cancer 4(12S), 2006.
152. Yap TA ,Vidal L, Pandha H, Spicer J, Coffey M, Kaye SB, Harrington KJ and De-Bono JS. A phase I study of wild-type reovirus, which selectively replicates in cells expressing activated Ras, administered intravenously to patients with advanced cancer. Eur J Cancer 4(12S), 2006.
153. Patel A, Williams D, O’Donoghue M, Paulsen A, Hare A, Yap TA, Elkin S, Kon OM. Comparison of two tuberculosis clinic services. Thorax 59(2):92 [P162], 2004.
154. Lee B, Neighbour H, Yap TA, Kon OM, Wright A, Elkin S. Baseline survey of practice in diagnosis and staging of carcinoma of the bronchus. Thorax 59(2):19 [S57], 2004.

Book Chapters

1. Yap TA, de Bono JS. AKT. In: Cancer Therapeutic Targets. Springer, 1-10, 2016.
2. Mateo J, Yap TA, de Bono JS. PARP Inhibitors. In: Management of Castration Resistant Prostate Cancer. Humana Press, 253-264, 2014.
3. Yap TA, Popat S. Emerging targets and new agents in lung cancer. In: Thoracic Tumours: Essentials for Clinicians. ESMO Press: Lugano, Switzerland, 73-76, 2014.
4. Mateo J, Ong M, Yap TA, de Bono JS. Opportunities And Pitfalls Of Targeted Therapeutic Combinations In Solid Tumors. In: Am Soc Clin Oncol Educ Book, 670-4, 2012.
5. Yap TA, Drew Y, Shanley S. Biology of BRCA1 and BRCA2 genes and implications for cancer management. In: The Translation of Biology to the Clinic. RCOG Press, 57-74, 2011.
6. Drew Y, Yap TA, Kaye SB. The future of PARP inhibitors in the treatment of cancer. In: Gynaecological Cancers: Biology and Therapeutics. RCOG Press, 83-98, 2011.
7. Yap TA, Kaye SB, Ashworth A, Tutt A. Tumour-specific synthetic lethality: targeting BRCA dysfunction in ovarian cancer. In: Emerging Therapeutic Targets in Ovarian Cancer. Springer-Verlag, 109-132, 2010.
8. Yap TA, Sarker D, Kaye SB, de Bono JS. Functional imaging: Clinical applications in molecular targeted therapy. In: Husband and Reznek’s Imaging in Oncology. 3rd. Informa Healthcare, 1366-1383, 2009.
9. Yap TA, Molife LR, de Bono JS. CDK inhibitors as anti-cancer agents. In: Checkpoint Responses in Cancer Therapy: Cancer Drug Discovery & Development. Humana Press, 135-162, 2008.
10. Ivy SP and Yap TA. In: Designing Trials for Drug Combinations.